Page Section: Centre Content Column
Decision 15HDC01542
Download the pdf version of this decision. (PDF 462Kb)
Names have been removed (except the experts who advised
on this case) to protect privacy. Identifying letters are assigned
in alphabetical order and bear no relationship to the person's
actual name.
District Health Board
Paediatric Registrar, Dr C
Pharmacy
Pharmacist, Ms B
Pharmacist, Ms D
A Report by the Health and Disability
Commissioner
Table of Contents
Executive
summary
Complaint and
investigation
Information gathered during
investigation
Relevant professional standards
Opinion: Introduction
Opinion: Dr C - Breach
Opinion: DHB - Adverse comment
Opinion: Ms B - Breach
Opinion: Ms D - Breach
Opinion: Pharmacy - Breach
Opinion: Ms E - Adverse comment
Recommendations
Follow-up actions
Appendix A: Independent paediatric advice to
the Commissioner
Appendix B: Independent pharmacy advice to the
Commissioner
Appendix C: Prescription form
Executive summary
1. Miss A, aged two years and 11 months,
experienced painful and difficult urination following bladder
surgery. She was reviewed for this on 8 September 2015 by
paediatric registrar Dr C at the Day Stay Unit of a public hospital
(the hospital). After discussion with a senior colleague, Dr C
prescribed some medications for Miss A including oxybutynin, which
is primarily indicated for the management of urinary urgency and
incontinence.
2. Dr C chose a dose of 2mg oxybutynin,
"because [Miss A's] weight was mid-range for her age, the dose is
mid-range for dosage and 2mg would be manageable for dispensing and
administering". Instead of writing "oxybutynin 2mg" three times
daily for ten days on the prescription form, Dr C wrote "oxybutynin
20mg", three times daily for ten days, which was a ten times higher
dose.
3. Miss A's father took the prescription
forms to the pharmacy that evening for the medications to be
dispensed. Pharmacist Ms B noticed that the oxybutynin dose seemed
high but did not question it at the time. The oxybutynin and one
other item were not in stock, so they were ordered for the next
day.
4. The following day, the oxybutynin and the
other item were delivered to the pharmacy. Ms B and the pharmacy
owner, pharmacist Ms D, were on duty. The prescription forms are
not initialled to show who completed the dispensing. The
medications were placed in a bag, and the bag was placed in the
delivery basket at the pharmacy. Ms D delivered the medication to
Miss A's mother. Ms D said that she omitted to discuss the
medication for Miss A with Miss A's mother, but discussed a
separate health issue.
5. Three days later, Miss A's mother gave
Miss A the prescribed dose of oxybutynin after she had ongoing pain
with passing urine. Miss A experienced side effects and was taken
to the hospital's Emergency Department, where she was monitored and
discharged later that day. Miss A experienced ongoing side
effects.
Findings
6. It was Dr C's responsibility to ensure
that she prescribed a clinically appropriate dose of oxybutynin to
Miss A. By failing to do so, Dr C did not provide services with
reasonable care and skill, and the Commissioner found that she
breached Right 4(1) of the Code of Health and Disability Services
Consumers' Rights (the Code).
7. The Commissioner considered that if
electronic prescribing had been available to Dr C when she
prescribed the medication to Miss A, it could have minimised the
risk of this error occurring.
8. Ms B failed to take steps to contact the
prescriber when she noticed that the oxybutynin dose seemed high.
Ms B also did not sign on the date stamp to indicate that she had
dispensed and/or checked Miss A's prescriptions in accordance with
the pharmacy's Dispensing Prescriptions Standard Operating
Procedure (SOP). The Commissioner found that Ms B did not provide
Miss A with services in accordance with professional standards, and
breached Right 4(2) of the Code.
9. The Commissioner was critical that Ms D
did not check the prescriptions, calculations and labels on 8
September 2015, did not ensure that the Dispensing Prescriptions
SOP was followed, and missed an opportunity to check the
appropriateness of the prescription for Miss A at the time of
delivery of the medications to Miss A's mother. The Commissioner
found that, in all the circumstances, Ms D did not provide services
to Miss A with reasonable care and skill, and breached Right 4(1)
of the Code.
10. Non-compliance with the Dispensing
Prescriptions SOP played a part in Miss A receiving an
inappropriate dose of oxybutynin. Accordingly, the Commissioner
found that the pharmacy did not provide services to Miss A with
reasonable care and skill and breached Right 4(1) of the Code.
11. The Commissioner was critical that the
pharmacy intern did not sign the prescription to indicate her
involvement in the dispensing process.
Recommendations
12. The Commissioner recommended that Dr C,
Ms B, Ms D and the pharmacy each provide a written apology to Mr
and Mrs A.
13. The Commissioner recommended that the
DHB introduce systems to allow a specific space for the recording
of a child's weight on prescriptions; give feedback to HDC on the
implementation of its new electronic prescribing system, and use
this case as an anonymised case study for education for paediatric
medical staff.
14. The Commissioner recommended that the
pharmacy undertake two audits of compliance with its Dispensing
Prescription SOP, and use this case as an anonymised case study for
education for future pharmacist or pharmacy intern employees of the
pharmacy.
15. The Commissioner recommended that the
Pharmacy Council of New Zealand consider whether a review of Ms B's
competence is warranted.
16. The Commissioner recommended that the
Ministry of Health actively continue to support the rollout of
electronic prescribing across New Zealand's DHBs in both inpatient
and outpatient settings, and work with the sector to progress an
integrated approach to medicines management.
Complaint and
investigation
17. The Commissioner received a complaint
from Mrs A about the services provided to her daughter, Miss A. The
following issues were identified for investigation:
• The appropriateness of the care provided
to Miss A by Dr C in September 2015.
• The appropriateness of the care provided
to Miss A by the DHB in September 2015.
• The appropriateness of the care provided
to Miss A by the pharmacy in September 2015.
• The appropriateness of the care provided
to Miss A by Ms B in September 2015.
• The appropriateness of the care provided
to Miss A by Ms D in September 2015.
18. An investigation was commenced on 31
March 2016.
19. The parties directly involved in the
investigation were:
Mrs A Complainant/consumer's mother
District Health Board Provider
Pharmacy Provider
Ms B Pharmacist
Dr C Paediatric registrar
Ms D Pharmacist
Ms E Pharmacy intern
Also mentioned in this report:
Mr A Miss A's father
Dr F Paediatric surgeon
20. Information was also reviewed from:
The Medical Council of New Zealand
The Pharmacy Council of New Zealand
21. Independent expert advice was obtained
from consultant paediatrician Dr Roger Tuck (Appendix A) and
pharmacist Sharynne Fordyce (Appendix B).
Information gathered during
investigation
Background
22. On 25 August 2015, Miss A, aged two
years and 11 months, had an operation by paediatric surgeon Dr F to
remove a urachal cyst from her bladder. Miss A was discharged
the following day. A urinary catheter was inserted during surgery
and then removed three days later. Miss A experienced worsening
dysuria (painful/difficult urination) following the catheter
removal and was prescribed a dose of oxybutynin that was too
high for a toddler. This report is about the care Miss A received
in relation to the prescribing and dispensing of oxybutynin in
September 2015.
8 September 2015
Day Stay Unit
23. On 8 September 2015, Miss A was seen at
the Day Stay Unit for review of her dysuria by paediatric registrar
Dr C.
24. Dr C examined Miss A and found that her
abdomen was soft and non-tender. Miss A had an ultrasound scan,
which showed thickening of the top of the bladder and a small
volume of free fluid adjacent to the bladder wall, which was likely
a result of her recent surgery. Dr C discussed Miss A's case with
Dr F, and they decided to start Miss A on a course of antibiotics,
analgesia (pain relief medication) and
oxybutynin.
25. Dr C handwrote the prescriptions for
Miss A on two separate DHB prescription forms (see Appendix C).
Regarding the oxybutynin prescription, Dr C stated:
"I … split the analgesia onto a separate prescription sheet and
referred to the appropriate medication dose in the New Zealand
Formulary for Children (NZFC). I split the analgesia because
this is commonly prescribed and administered whereas the other
medication is less so and I wanted to reduce the risk of an error.
The dose range [for oxybutynin] for patients 2-5 years is
1.25-2.5mg and I chose 2.0mg because [Miss A's] weight was
mid-range for her age, the dose is mid-range for dosage and 2mg
would be manageable for dispensing and administering. I documented
the on-call contact number which is routine practice to enable
checking of the medication if there is a query about the medication
or dosage or frequency by either the pharmacy or parents. The
on-call phone is manned 24/7 by a surgical registrar."
26. Instead of writing "oxybutynin 2mg"
three times daily for ten days on the prescription form, Dr C wrote
"oxybutynin 20mg", three times daily for ten days, which was a ten
times higher dose. Dr C also documented Miss A's weight, 14kg, on
both prescription forms. Dr C later told HDC that "the prescription
read 20mg rather than 2.0mg".
27. The DHB confirmed that Dr C received an
orientation booklet as part of her registrar training, which
included guidelines on safe prescribing and links to the hospital's
prescribing guidelines. The hospital's prescribing guidelines
state: "Never write a trailing zero after a whole number ie
8mg, not 8.0mg."
28. Miss A was discharged with a plan to
review her in one week's time (on 15 September 2015) at the
registrar clinic.
The pharmacy
29. Miss A's father, Mr A, took the
prescriptions to the pharmacy at around 5pm on 8 September
2015 for the medications to be dispensed. Ms B was the
pharmacist on duty and was working with pharmacy intern Ms
E.
30. Ms B said that Ms E took the
prescriptions from Mr A and began processing them through the
computer. Ms E told HDC that she does not recall whether she
entered the prescriptions into the computer, but does recall being
involved in the dispensing of some medications for Miss A that were
in stock.
31. Ms B said that she informed Mr A that
the oxybutynin and the lignocaine gel were not in stock and could
be ordered for the next day, but that the rest of the medications
could be dispensed at that time.
32. Ms B said that Ms E began working on
dispensing the medications. Ms B stated: "I had to help [Ms E]
calculate the volume required for the doses of Augmentin,
Paracetamol, Ibuprofen and Tramadol, because she was struggling to
convert the [milligrams] on the prescription to [millilitres]
required for dosing." Ms B stated that she reconstituted the
antibiotic suspension while Ms E dispensed the other items on
the prescription.
33. Ms B told HDC that, as she was checking
the medication labels, she noticed that oxybutynin had been entered
into the computer as tablets, rather than as the liquid that had
been prescribed. Ms B told HDC that she "noticed that the dose
seemed high, but did not question it at the time". Ms B stated: "I
acknowledge that I should have attempted to contact the prescriber
regarding the high dose of oxybutynin at that time instead of
leaving it for later, regardless of what time of day it was."
34. Ms B generated a new oxybutynin label to
read a liquid formulation and put it to one side with the
prescriptions, to complete the dispensing when the new stock
arrived the next day. Ms B then ordered the oxybutynin and the
lignocaine gel.
35. Pharmacy owner and pharmacist Ms D told
HDC that she was out of the pharmacy on 8 September 2015 when the
prescription was received, but that she arrived back at around
5.30pm, just as the last of the in stock medications for Miss A
were being dispensed. Ms D said that she helped by dealing with
other prescriptions that were waiting to be completed, so that Ms B
and Ms E could concentrate on Miss A's prescriptions.
36. Ms D said that, after the medications
were given to Mr A, Ms B expressed frustration to her regarding Ms
E's inability to calculate the volumes required accurately. Ms D
stated: "In hindsight, this should have been my [c]ue to check the
entire prescription but I didn't." Ms D also told HDC: "I have
faith in [Ms B's] capabilities that she would have corrected any
errors. At the time I had no need to double check her work."
37. The prescriptions for Miss A's
medications are not initialled or signed to show who carried out
the dispensing or checking. However, there are some annotations on
the prescriptions. Ms D advised HDC that these are mainly written
by Ms B, but that some had been written and scribbled out by Ms E.
Ms D stated that often Ms E wrote calculations on scrap bits of
paper and discarded them, rather than annotating them on the
prescription as instructed, "mak[ing] it very difficult to prove
who did what on the prescription". Ms D stated that the annotations
by Ms B indicate that she had to take over because Ms E was unable
to do the calculations.
9 September 2015
38. On 9 September 2015, Ms B and Ms D were
the pharmacists on duty at the pharmacy, and there was also a
pharmacy student present. Ms E was not working, as it was her
regular day off.
39. The oxybutynin liquid and lignocaine gel
were delivered to the pharmacy at around 11am. The medications were
then labelled and bagged for delivery. However, the prescriptions
are not initialled or signed to show who dispensed or checked these
items. Ms B and Ms D both told HDC that they are unsure who
completed the dispensing by labelling and bagging the medications,
and whether a final check was carried out. Ms D stated: "As there
are no signatures on the prescription for the dispensing of this
item, as the owner I will take responsibility as it was either [Ms
B] or myself, we just cannot be certain."
40. The bag of medications was placed in the
delivery basket at the pharmacy. That afternoon, Ms D delivered the
medications to Miss A's mother, Mrs A. Mrs A told HDC that the
medications were delivered to her house in a brown bag. She
stated:
"[The pharmacist] knew I had two very sick kids so I think they
were saving me a trip back with one vomiting baby and one toddler
beside herself in pain after having bladder surgery. I asked the
pharmacist about the oxybutynin and she said they very rarely use
it, that it can cause sedation."
41. Ms D stated that she "chatted with [Mrs
A] in regards to a separate health issue concerning her other
daughter … At no point did I discuss the prescription for [Miss
A]." Ms D said that, while she omitted to discuss the medication
for Miss A, she told Mrs A that if she had any questions she could
call her or Ms B at any time.
12 September 2015
42. On the morning of 12 September 2015, Mrs
A administered Miss A 20ml of oxybutynin. Mrs A told HDC that she
was nervous about using the oxybutynin, and that she recalls having
the medication for a few days before she gave it to Miss
A.
43. Mrs A stated:
"As soon as I gave it, I thought that is an awful lot of
medicine to get in to a child. I […] quickly googled, and
discovered that this was an almost TEN TIMES overdose of a very
dangerous drug. I rushed her to [the hospital] which is 15 minutes
from my house. By the time I got there, she was blind from dilated
pupils, was hallucinating and was starting to slur her
words."
44. Miss A was reviewed in the Emergency
Department (ED) at 8.10am by a paediatric registrar, who recorded
on the discharge summary:
"Almost 3 year old girl presents after taking a 7 x the standard
dose of oxybutynin at home as per the prescription. This equates to
1.4mg/kg (normal dose is 0.2mg/kg). Mother feels that [Miss A is]
finding it difficult to see looking at toast closely, pupils
dilated. Starting to sway. Not her normal self … [Miss A] has
ongoing pain with passing urine last night. Therefore, mother gave
oxybutynin this morning."
45. The paediatric registrar examined Miss A
and noted that her heart rate was 126 beats per minute, her
respiration rate was 30 breaths per minute, her oxygen saturation
was 100%, her temperature was 37.3°C, and her blood sugar level was
5.1mmol/L. These observations are all within the normal range for a
child of Miss A's age.
46. The paediatric registrar's impression
was that Miss A had some signs of mild anticholinergic
toxicity. Miss A had initial and repeat electrocardiograms,
which were normal.
47. Mrs A told HDC that Miss A had tremors
and jerky movements, was sedated and difficult to rouse, she could
not speak, and she had a high heart rate.
48. At 1.30pm, Miss A was reviewed by a
paediatric surgical registrar, who recorded that he would
follow up with the pharmacy and prescriber to find out how the
error had happened, to stop it happening again.
49. Ms D told HDC that she was contacted by
the registrar, who told her what had happened. Ms D said that she
then left a telephone message for Mrs A apologising for the
error.
50. It is documented in the clinical notes
that Miss A had myoclonic jerks while she was asleep in the
ED that afternoon. Miss A was discharged from the ED at around 5pm.
The discharge summary states that Miss A was alert and comfortable
at rest and had bilaterally dilated pupils. The discharge advice
was to continue taking the appropriate dose of oxybutynin the next
day if required (2.8ml three times daily or as needed) and to
return for review if Miss A had any abnormal behaviour, vomiting,
urinary retention, or worsening vision, or if her parents were at
all concerned.
13-15 September 2015
51. Dr C told HDC that, on 13 September
2015, the registrar told her about Miss A's admission to the ED the
previous day, and that the registrar had contacted the pharmacy,
had a photocopy of the prescription emailed from the pharmacy to
the ED, and had alerted Dr F to the error. Dr C said that she
discussed her error with the Clinical Director of Paediatric
Surgery on Monday 14 September 2015.
52. Ms D told HDC that, on 14 September
2015, all pharmacy staff involved in the dispensing of Miss A's
prescriptions convened to discuss what had happened and establish
how the error had occurred, and to discuss how to prevent further
incidents such as this occurring.
53. On 15 September 2015, Dr C reviewed Miss
A with Mrs A at the registrar clinic, as had been arranged
previously. Dr C said that she apologised for the error at this
time, and that Mrs A was understandably very upset.
Subsequent events
54. Mrs A told HDC that Miss A had the
following side effects after the overdose of oxybutynin: several
days of lethargy; confusion and slurring her words; four days of
severe abdominal pain, restlessness and difficulty urinating; two
weeks of low grade fever; three days later, vomiting; and, four
weeks later, bleeding from her rectum. Mrs A was also concerned
that the overdose caused slow healing at Miss A's bladder surgery
site, and urinary retention. Miss A was seen for those issues in
the ED on 17 September, 28 September, and 4 October 2015.
Further information - the pharmacy
Apology letter
55. On 16 September 2015, Ms B wrote a
letter of apology to Mr and Mrs A, which stated:
"As a pharmacist, it was my responsibility to query the high
dose of oxybutynin that was on the prescription and I failed to do
that.
As a result of this incident, we have reviewed our dispensing
procedures to ensure that similar mistakes won't happen to you or
anyone else in the future …
Once again I am very sorry that this occurred and offer my
humble apologies for the distress and inconvenience caused. I would
like to offer to pay for any ambulance fees or medical expenses
that were incurred as a direct result of my error."
Incident Notification form
56. On 17 September 2015, Ms B filled in an
Incident Notification form. She recorded that Mrs A contacted her
on 13 September 2015 to inform her of the error. The Incident
Report form states:
"Details of the incident [Prescription] from hospital with lots
of doses to be calculated. Oxybutynin dose written as 20mg [three
times daily for ten days]. I noticed the dose was high but didn't
check it. The stock needed to be ordered so was dropped off by [Ms
D] on the 9th Sep. The first dose was given on the 11th Sep and
[Miss A] experienced anticholinergic [side effects] so was taken to
hospital. [Mrs A] called the pharmacy on Sunday to notify [Ms D] of
what had happened …
Action requested by customer Letter of apology and review
processes. Contact registrar that was responsible at hospital.
Action taken by pharmacy after the event and by whom … [Ms D]
and [Ms B] went through the dispensing SOP and updated the
procedures relating to suspensions and child doses. Wrote a letter
of apology …
Investigation of incident … Pharmacy was busy -> 3
[prescriptions] happening at the same time. [Prescription] had 6
doses that needed calculating. Intern made an error when processing
[prescription] -> tablets rather than suspension. Dose was not
checked / discharge summary was not looked at.
Outcome: correction action taken … Letter of apology written and
given to parents. SOP updated."
Dispensing Prescriptions Standard Operating Procedure
(SOP)
57. The Dispensing Prescriptions SOP (issue
date 7 March 2014) in place at the time of the error stated:
"Purpose: To describe the process of dispensing in this pharmacy
to ensure that prescriptions are dispensed accurately and in
accordance with legislative and ethical requirements …
Checking Procedures
During dispensing process: …
• Check medicine dose, frequency
interactions and contraindications, to ensure the medicine is being
given appropriately (e.g. correct dose for age or condition) …
• Dispenser and checker must be identified
on all prescriptions and original dispensing, by signing on the
date stamp …
Handing out procedures / Giving advice to customers
• It is the sole responsibility of the
pharmacist to hand out prescriptions, or delegate this task
ensuring that the necessary information and counselling is given to
the patient."
58. The SOP was updated on 16 September 2015
to include the following section on calculations for child
doses:
"Calculations for child doses
• Write out the full calculation on the
prescription so that it can be checked at each step of
dispensing.
Dose (ml) = Dose (mg)
X mg/kg = X mg/dose
X mg/dose = X ml/dose
• If no weight is
available for the child, calculate the expected weight for the
prescribed dose and leave a 'check weight' label with the
medication.
• Check that the dose is appropriate for the
child's weight and age according to the Paediatric Pharmacopoeia or
NZF.
• If the dose is low or high, notify the
pharmacist on duty to deal with it appropriately."
Ms D
59. Ms D stated that "the prescriber should have been contacted
and [oxybutynin] not dispensed until this could occur and the dose
been discussed". She told HDC:
"I must remind all pharmacists that clinical checks need to be
done on every prescription to ensure the dose is appropriate for
the patient. This was a prescribing error that was not picked up,
and as pharmacists we are responsible for the last check."
60. Ms D told HDC: "I cannot explain why the prescriptions were
not initialled as being dispensed and checked, as this is part of
the pharmacy SOPs. I admit that we had not been very good at making
people accountable for this, but we are now." Ms D acknowledged
that as the owner and director of the pharmacy, it is her
responsibility to ensure that all dispensary staff follow the SOPs
in place.
61. Ms D stated that she continues to monitor all dispensary
staff to ensure they follow the SOPs in place at the pharmacy, and
that staff are more diligent in ensuring that all prescriptions are
initialled by the dispenser and checker, and that all calculations
are recorded on the prescriptions, rather than on scrap bits of
paper. Ms D said that, in future, she will undertake random checks
on prescriptions dispensed to ensure that the pharmacy SOPs are
being followed.
62. In September 2014, the pharmacy had undergone a quality
audit for the Ministry of Health. The audit found that many of the
pharmacy's prescriptions did not include the name of the pharmacist
responsible for the final check for completeness and accuracy.
Following the audit, Ms D had confirmed in writing to the auditor
that "all prescriptions, including repeats and owes, will be
initialled by the checking pharmacist". Following this confirmation
(and clarification of some other matters), all audit criteria were
fully attained on 24 November 2014.
Further information - Ms B
63. Ms B told HDC that she has been involved in reviewing the
Dispensing Prescriptions SOP, has become much more cautious in her
dispensing, has improved her practice regarding initialling
prescriptions, makes sure that she calculates the exact dose by
weight for prescriptions for children, asks to read any discharge
summary available to ensure it aligns with the prescription, and
writes out all calculations in full on the prescription. She stated
that the pharmacy has placed a list of the usual doses that require
calculation next to the dispensing computer to make it easier
to check doses, now keeps the paediatric pharmacopoeia on
hand for other doses, and has "check weight" and "check dose"
labels to put with prescriptions where the weight is listed on the
prescription.
64. Ms B told HDC:
"The incident … has made us all strive to improve our pharmacy
practice and communication with each other. I am so incredibly
sorry that this happened and I'm doing everything I can to ensure
that I don't do it again."
Subsequent events - Dr C
65. Dr C told HDC: "I would like to apologise again for [the]
distress that this has caused [Miss A] and her family."
66. Dr C told HDC that she raised the error through her
department's morbidity and mortality meeting, and it was discussed
as a team. She stated:
"There was discussion regarding contributory factors; ensuring
safeguards are reviewed and the whole team learns from the mistake
to minimise the risk of this incident occurring in future.
The following points were discussed as learning points which I
have put into practice:
1. Trailing zeros - I don't usually use trailing zeros, but I
believe I did in this case because the range as specified in the
NZFC had fractions of a mg in each case with a decimal point in
each dose (eg. 1.25 and 2.5mg).
2. Using digital prescribing where possible -
currently, there are 2 systems of prescribing - a paper system and
a digital system. I previously used the 2 interchangeably, but in
an effort to ensure accuracy, I will use the digital system in
future. However, this is not possible in the outpatient clinic due
to the way the computer system is set up. The electronic
prescription system does require the weight of a patient to be
manually written after printing as it is not currently considered
essential when prescribing.
3. Re-review the prescriptions before handing
them to patients.
4. Continue to refer to prescription guides
e.g. NZFC.
5. Continue to include a contact telephone
number and patient's weight on prescriptions to facilitate
checking.
Once again, I was deeply saddened by [Miss A's]
experience; it has provided me with invaluable education for my
future. I will do everything possible in future to ensure this
situation is not repeated."
67. Dr C also told HDC that she has carried out a literature
review on medical error, which emphasised the importance of
optimising the prescribing environment, checking mechanisms and
improving systemic factors to reduce error. She stated that she has
since avoided prescribing in noisy or busy environments, printed
prescription guidelines and placed them in medication charts,
encouraged an open dialogue with nursing staff, become more engaged
with the Riskpro risk alert system, and progressed her active
involvement with hospital audits.
68. In May 2016, a senior pharmacist from the DHB audited Dr C's
prescribing while Dr C was working in the Neonatal Intensive Care
Unit. She reviewed 51 of Dr C's prescriptions over the period of
two weeks and, without exception, found these to be clinically
appropriate, legible, legally complete, and in accordance with
standard prescribing practice and relevant protocols. The
pharmacist told HDC that she discussed safe prescribing practices
with Dr C, and stated:
"[I] am confident that she has a good understanding of the
importance of prescribing legibly and completely, minimising
distractions during prescribing, and utilising appropriate dosing
resources for the clinical situation, as well as being aware of the
availability of various prescribing resources."
Subsequent events - the DHB
69. The Clinical Director of Paediatric Surgery told HDC:
"On behalf of our department, I too apologise to the family for
this error occurring. We recognise[d] the seriousness of the error
at the time and as a result, the following actions were taken:
1. [Dr C] self-reported this error promptly through our
departmental morbidity review processes.
2. We have addressed the error through rigorous peer review in
our department and agreed with [Dr C's] actions, as outlined
above.
3. We are confident that this does not represent a systemic
problem or an educational omission in registrar training.
4. This incident provided us with the opportunity to discuss and
reflect on safe prescribing practices. We have ensured that all
members of our team know where to access prescribing information
and advice. However, this was not an issue in this case.
5. We have activated a Riskpro so the incident can be reviewed …
with our departmental protocols.
6. We are satisfied that [Dr C] has learned from this event
including discussion through the Morbidity and Mortality process.
This event has highlighted to all members of our medical team, the
critical importance of accurate prescribing using accepted
methodologies and terminology and the consequences of inattention
to detail."
70. The DHB agreed with HDC's expert advisor that having a space
to document the weight of a child on outpatient prescriptions would
be a useful addition for safety. In the provisional opinion, I
recommended the DHB introduce systems to allow a specific space for
the recording of a child's weight on prescriptions. In response to
the provisional opinion, the DHB advised that it has now amended
its prescription form to include a space to document the weight of
a child under 13 years of age.
71. The DHB's electronic prescribing and
administration (ePA) programme started being introduced from
mid-2016 to cover both inpatient and outpatient prescribing. the
DHB advised that the MedChart ePA system has now been
implemented on two wards, and a project plan for further roll-out
of ePA is being developed, aligned to the Electronic Health Record
strategy (to implement a single electronic health record for the
whole region and sector).
72. The DHB has since introduced a paediatric
prescribing memory aid in the form of a safe prescribing reference
card, which is given to all house surgeons and registrars. This is
a small card that is clipped in with identity and swipe cards. It
states:
"Right patient correct sticker on all pages AND clearly
written name and weight
Right medicine document generic name … LEGIBLY
Right dose and route calculate per kg (or m²) - sensible
rounding, don't exceed adult dose … document mg/kg dose for ease of
checking
Right time indication for [as needed] meds, date/time for
once-only meds, consider dose interval …
Identify yourself! Signature + surname + date when starting AND
ceasing medicines …"
The back of the card then directs staff to websites for
resources for prescribing in children.
73. The DHB told HDC that it is developing
its clinical excellence and safe care programmes to ensure that
minutes are taken at its morbidity and mortality meetings,
and the learnings from adverse events are disseminated
throughout the DHB.
Further information - electronic
prescribing
74. In the Ministry of Health's National Health IT Plan Update
2013/14 it specified that all DHBs were expected to have electronic
prescribing and administration (ePA) in place by 2016, and a
national contract has been signed that supports a standardised
approach to implementing electronic prescribing. Nine of New
Zealand's 20 DHBs have implemented, or are in the process of
implementing, ePA.
75. The Ministry of Health told HDC that the
ePA system, MedChart, is currently being enhanced to enable its use
in outpatient settings, and this will be available for early
adopter testing in early 2017. Following the successful early
adopter testing in outpatient settings, the Ministry of Health said
that it will continue to work with DHBs to progress the rollout of
ePA across hospital inpatient and outpatient settings. The Ministry
of Health stated that it is also working with the sector (hospital
and community) to develop a more integrated approach to medicines
management across the New Zealand health system.
Responses to the provisional opinion
76. Responses to the provisional opinion were received from all
parties, and a response to the "information gathered during
investigation" section of the provisional opinion was received from
Mrs A. Where appropriate, responses have been incorporated into the
"information gathered during investigation" section
above.
77. Ms B, Ms D, the pharmacy and Ms E
confirmed that they had no comments in response to the provisional
opinion.
78. Dr C confirmed that she would write a
letter of apology to the family as recommended. She also stated
that she continues to maintain heightened levels of vigilance over
her practice, and uses the digital prescribing system at the DHB
where possible.
79. The DHB confirmed that it would advise
HDC of further actions undertaken in due course.
80. Mrs A told HDC that, following the
overdose, Miss A struggled to urinate for days and would scream in
pain for hours at a time without being able to sleep or eat much.
Mrs A said that it took Miss A three to four months to be able to
urinate properly, and that she had been doing reasonably well up
until the overdose. Mrs A is concerned that Miss A may now have
autonomic dysfunction as a result of the medication
reactions.
Relevant
professional standards
81. The Pharmacy Council of New Zealand (PCNZ) Competence
Standards for the Pharmacy Profession (2015) state:
"M1.2 Comply with ethical and legal requirements …
O1.3.3 Uses professional judgement to determine whether changes
to the medication treatment regimen are needed to improve safety,
efficacy or adherence
O1.3.4 Liaises with and provides recommendations to the
prescriber and/or the other healthcare professionals to ensure
optimal use of medicines by patients …
O3.1.3 Applies knowledge in undertaking a clinical assessment of
the prescription to ensure pharmaceutical and therapeutic
appropriateness of the treatment and to determine whether any
changes in prescribed medicines are warranted
O3.1.4 Initiates action, in consultation with patient/carer
and/or prescriber to address identified issues."
82. The PCNZ Code of Ethics (2011) states:
"1.2 Take appropriate steps to prevent harm to the patient and
public …
5.1 Be accountable for practising safely and maintain and
demonstrate professional competence relative to your sphere of
activity and scope of practice."
Opinion:
Introduction
83. This case is an unfortunate example of errors occurring in
tertiary hospital outpatient clinic and community pharmacy
settings, which allowed for a child to be administered medication
in a dose that was clinically unsafe.
84. It is essential that all providers involved in the
prescribing and dispensing of medication remain attentive to the
possibility of errors occurring at different steps in the process.
Providers must take great care to ensure they have performed their
role in the process accurately.
Opinion: Dr C -
Breach
85. Under Right 4(1) of the Code, Miss A had the right to have
services provided by Dr C with reasonable care and skill.
86. On 8 September 2015, after discussing Miss A's case with Dr
F, Dr C handwrote Miss A's prescriptions on two prescription forms.
Dr C explained that she wrote the oxybutynin prescription on a
separate form because it is less commonly prescribed than the other
medications. Dr C told HDC that she referred to the appropriate
medication dose in the NZFC and that she chose a 2mg dose because
"[Miss A's] weight was mid-range for her age, the dose is mid-range
for dosage and 2mg would be manageable for dispensing and
administering".
87. Instead of writing "oxybutynin 2mg" on the prescription
form, Dr C wrote "oxybutynin 20mg" - a ten times higher dose. Dr C
also documented Miss A's weight, 14kg, on both prescription forms.
Dr C told HDC that she does not usually use trailing zeros (eg,
2.0mg instead of 2mg), but believes she did in this case because
the range as specified in the NZFC had fractions of a milligram
with a decimal point in each dose (eg, 1.25 and 2.5mg). Dr C later
told HDC that "the prescription read 20mg rather than 2.0mg".
88. The DHB confirmed that Dr C received an orientation booklet
as part of her registrar training, which included guidelines on
safe prescribing and links to the prescribing guidelines. The
prescribing guidelines state: "Never write a trailing zero after a
whole number ie 8mg, not 8.0mg." Despite Dr C's explanation, I am
concerned that she did not follow the prescribing guidelines
regarding trailing zeros in this case.
89. I am satisfied that Dr C's error was a transcribing error
that occurred when she wrote the dose on the prescription form, as
she had taken steps to choose a clinically appropriate dose.
Nevertheless, Dr C recorded on the prescription form a dose that
was significantly higher than recommended for a child of Miss A's
age and weight. My expert advisor, paediatrician Dr Roger Tuck,
advised:
"The prescription error, as with all prescription errors, was
unacceptable … prescribing and dispensing errors are unquestionably
serious departures from acceptable standards of care."
90. I accept Dr Tuck's advice. It was Dr C's responsibility to
ensure that she prescribed a clinically appropriate dose of
oxybutynin to Miss A. By failing to do so, she did not provide
services with reasonable care and skill and breached Right 4(1) of
the Code.
91. I consider that, once Dr C was aware that the error had
occurred, she took appropriate steps to disclose it and to minimise
the risk of such an error occurring again.
Opinion: DHB -
Adverse comment
92. At the time of these events, Dr C was an employee of the
DHB. In addition to any direct responsibility for a breach of the
Code, under section 72(2) of the Act, employers are responsible for
ensuring that their employees comply with the Code. Pursuant to
section 72(5) of the Act, it is a defence for an employing
authority to prove that it took such steps as were reasonably
practicable to prevent the acts or omissions leading to an
employee's breach of the Code.
93. At the time of these events, electronic prescribing was
available at the DHB but not in the outpatient clinic setting. I
consider that, if electronic prescribing had been available to Dr C
when she prescribed the medication to Miss A in the Day Stay Unit,
it could have minimised the risk of this error occurring.
94. The DHB confirmed that Dr C received an orientation booklet
as part of her registrar training, which included guidelines on
safe prescribing and links to the prescribing guidelines.
Accordingly, I do not consider that this error represents a failure
with regard to orientation or training provided to Dr C. I am
satisfied that the error in failing to prescribe a clinically
appropriate dose of oxybutynin to Miss A was Dr C's alone, given
that she had taken steps to choose a clinically appropriate dose,
but failed to transcribe this accurately.
95. My expert advisor, paediatrician Dr Roger Tuck, advised:
"Digital systems are in their infancy in NZ. In the meantime,
continuing education of clinical staff on manual prescribing with
continuing innovation to mitigate risks is essential."
96. The DHB told HDC that its new e-prescribing programme, which
is being introduced from mid-2016, will cover both inpatient and
outpatient prescribing. I consider it both necessary and
appropriate that this is being introduced. The DHB has advised that
it has also introduced a paediatric prescribing memory aid in the
form of a safe prescribing reference card, which is given to all
house surgeons and registrars. I am satisfied that the actions
taken by the DHB following the error are appropriate in the
circumstances.
Opinion: Ms B -
Breach
97. As a registered pharmacist, Ms B is responsible for ensuring
her adherence to professional standards. The PCNZ competence
standards require that a registered pharmacist "[a]pplies knowledge
in undertaking a clinical assessment of the prescription to ensure
pharmaceutical and therapeutic appropriateness of the treatment and
to determine whether any changes in prescribed medicines are
warranted". The PCNZ Code of Ethics requires registered pharmacists
to be accountable for practising safely and for maintaining and
demonstrating professional competence.
98. The Pharmacy Dispensing Prescriptions SOP required Ms B to:
"Check medicine dose, frequency interactions and contraindications,
to ensure the medicine is being given appropriately (eg. Correct
dose for age or condition)."
99. Ms B was the pharmacist on duty on 8 September 2015, and was
working with pharmacy intern Ms E. Ms B told HDC that, as she was
checking the medication labels for Miss A's prescriptions on 8
September 2015, she "noticed the dose [of oxybutynin] seemed high,
but did not question it at the time". Ms B stated: "I acknowledge
that I should have attempted to contact the prescriber regarding
the high dose of oxybutynin at that time instead of leaving it for
later, regardless of what time of day it was." Ms B put the
oxybutynin label to one side with the prescription, to complete the
dispensing when the new stock arrived the next day.
100. My expert advisor, pharmacist Sharynne Fordyce,
advised:
"This dose of 20mg three times daily is three times the maximum
dose for an adult, and is not recommended for use in children under
5 years of age. Therefore accepted practice would have been to
contact the prescriber and not to dispense the medicine until the
dose had been clarified. Not to have done so would be viewed by
myself and my peers as a serious departure from the accepted
standard of care."
101. I accept Ms Fordyce's advice. I am particularly concerned
that, despite Ms B noticing that the oxybutynin dose seemed high
for a child Miss A's age, she did not take steps to contact the
prescriber as required by the PCNZ Competence Standards for the
Pharmacy Profession and the Pharmacy's Dispensing Prescriptions
SOP.
102. The prescriptions for Miss A's medications are not
initialled or signed to show who carried out the dispensing or
checking. The Dispensing Prescriptions SOP required Ms B to sign on
the date stamp to indicate whether she dispensed and/or checked the
prescription. I am critical that she did not do so.
103. Ms B was one of two pharmacists working at the pharmacy on
9 September 2015 when the oxybutynin stock arrived at the pharmacy
and was labelled and bagged for delivery. Given that there are no
signatures on the prescription to indicate who completed the
dispensing or carried out the final check, and neither Ms B nor Ms
D can recall who did this, I am unable to make a finding as to
whether Ms B completed the dispensing of this prescription or
carried out the final check.
104. In conclusion, Ms B failed to take steps to contact the
prescriber when she noticed that the oxybutynin dose seemed high,
as required by the PCNZ Competence Standards for the Pharmacy
Profession and the pharmacy's Dispensing Prescriptions SOP. Ms B
also did not sign on the date stamp to indicate that she had
dispensed and/or checked Miss A's prescriptions on 8 September 2015
in accordance with the pharmacy's Dispensing Prescriptions SOP.
Accordingly, I consider that Ms B did not provide Miss A with
services in accordance with professional standards, and breached
Right 4(2) of the Code.
Opinion: Ms D -
Breach
105. On 8 September 2015, Ms D arrived back at the pharmacy as
the last of the in stock medications were being dispensed for Miss
A. Ms D said that, after the medications were given to Mr A, Ms B
expressed frustration to her regarding Ms E's inability to
calculate the volumes required accurately. Ms D stated: "In
hindsight, this should have been my [c]ue to check the entire
prescription but I didn't."
106. My expert advisor, pharmacist Sharynne Fordyce,
advised:
"[Ms D] had been made aware of [Ms B's] concern for [Ms E's]
inability to independently complete the calculations involved with
the doses on the prescription. As [Ms E's] preceptor, and the
senior pharmacist present, good practice would have suggested [Ms
D] check the prescription, calculations and labels, as she herself
admitted later."
107. In the circumstances, I am critical that Ms D did not check
the prescriptions, calculations and labels on 8 September
2015.
108. Ms D was one of two pharmacists working at the pharmacy on
9 September 2015 (the other was Ms B) when the oxybutynin stock
arrived at the pharmacy and was labelled and bagged for delivery.
There was also a pharmacy student working at the pharmacy that day.
Given that there are no signatures on the prescription to indicate
who completed the dispensing or carried out the final check, and
neither Ms D nor Ms B can recall who did this, I am unable to make
a finding as to whether Ms D completed the dispensing of this
prescription or carried out the final check. I am critical that, as
the owner and director of the pharmacy, Ms D did not ensure that
the Dispensing Prescriptions SOP was followed in this
regard.
109. The oxybutynin and lignocaine gel were put aside in a bag
for delivery and, on the afternoon of 9 September 2015, Ms D
delivered the medications to Miss A's mother, Mrs A. Mrs A told HDC
that the medications were delivered to her house in a brown bag.
She stated:
"[The pharmacist] knew I had two very sick kids so I think they
were saving me a trip back with one vomiting baby and one toddler
beside herself in pain after having bladder surgery. I asked the
pharmacist about the oxybutynin and she said they very rarely use
it, that it can cause sedation."
110. However, Ms D said that she "chatted with [Mrs A] in
regards to a separate health issue concerning her other daughter".
Ms D stated: "[A]t no point did I discuss the prescription for
[Miss A]." Ms D said that she told Mrs A that if she had any
questions she could call Ms D or Ms B at any time.
111. I note Ms Fordyce's advice:
"Not discussing the contents of the bag before handing over the
prescription is … a departure from good practice … I would consider
this departure to be a moderate to severe one as it was another
lost chance to check the dose, and talk to the parents."
112. In my view, the discussion on delivery of the medications
to Mrs A was a missed opportunity for Ms D to check the
appropriateness of the prescription for Miss A, and I am critical
that she did not do so.
113. Accordingly, in the circumstances, I find that Ms D did not
provide services to Miss A with reasonable care and skill, and
breached Right 4(1) of the Code.
Opinion:
Pharmacy - Breach
114. The pharmacy was responsible for ensuring that the pharmacy
provided services to Miss A with reasonable care and skill. This
includes the need to ensure staff compliance with its SOPs.
Pharmacies are responsible for the operation of services provided
by their staff, and can be held responsible for individual failures
by staff. While the individual pharmacists in this case also bear
responsibility for the deficiencies in the care provided to Miss A,
I am of the view that the deficiencies were also a result of issues
at the pharmacy.
115. Consumer safety is of the utmost importance, and I consider
that it is the responsibility of the pharmacy to ensure that every
staff member complies with its SOPs, in order to prevent harm to
patients. PCNZ, in its document "Writing Standard Operating
Procedures", has stated that procedures are the cornerstone of a
strong quality system and support meeting the overall goal of
providing the public with safe and effective medical products.
116. I accept Ms Fordyce's advice that, at the time of the
error, the pharmacy had in place an appropriate Dispensing
Prescriptions SOP. However, I am concerned that more than one staff
member failed to follow the Dispensing Prescriptions SOP, as there
are no initials on the prescription to indicate who dispensed, and
who performed the final check of, the medications dispensed on 8
September 2015, and of the oxybutynin and lignocaine gel dispensed
the next day.
117. Furthermore, I am concerned that the high dose of
oxybutynin was dispensed without the dose first being clarified
with the prescriber, despite the Dispensing Prescriptions SOP
stating: "Check medicine dose, frequency interactions and
contraindications, to ensure the medicine is being given
appropriately (eg. correct dose for age or condition)."
118. Without staff compliance, policies become meaningless.
Ultimately, the pharmacy had a responsibility to ensure that all
staff complied with its SOPs and provided services of an
appropriate standard. I consider that the pharmacy is responsible
for the person who completed the dispensing and final check of the
oxybutynin on 9 September 2015 not being identifiable. In my
opinion, non-compliance with the Dispensing Prescriptions SOP
played a part in Miss A receiving an inappropriate dose of
oxybutynin. Accordingly, I consider that the pharmacy did not
provide services to Miss A with reasonable care and skill and
breached Right 4(1) of the Code.
119. Ms Fordyce advised me that the actions taken by the
pharmacy and its staff following these events were timely and
appropriate. She stated that the changes made to the Dispensing
Prescriptions SOP are very detailed, particularly in regard to
dosage calculations for children, and are appropriate. I accept
this advice.
Opinion: Ms E - Adverse comment
120. Ms E was the pharmacy intern working on 8 September 2015
when Mr A attended the pharmacy with the prescriptions for Miss A's
medications. Ms E was working with pharmacist Ms B.
121. Ms B said that Ms E took the prescriptions from Mr A and
began processing them through the computer.
122. Ms B stated: "I had to help [Ms E] calculate the volume
required for the doses of Augmentin, Paracetamol, Ibuprofen and
Tramadol, because she was struggling to convert the [milligrams] on
the prescription to [millilitres] required for dosing." Ms B stated
that she reconstituted the antibiotic suspension while Ms E
dispensed the other items on the prescription.
123. Ms E told HDC that she does not recall whether she entered
the prescriptions into the computer, but does recall being involved
in the dispensing of some medications for Miss A that were in
stock.
124. The pharmacy's Dispensing Prescriptions SOP required Ms E
to sign on the date stamp to indicate that she dispensed the
prescription. My expert advisor, pharmacist Sharynne Fordyce,
stated that all persons involved in the dispensing process "were
responsible for initialling or signing for the process they carried
out, so as to identify the processor, dispenser and checker". I am
critical that Ms E did not sign the prescription to indicate her
involvement in the dispensing process.
Recommendations
125. I recommend that Dr C, Ms B, Ms D and the pharmacy each
provide a written apology to Mr and Mrs A, and send this to HDC for
forwarding to Mr and Mrs A within three weeks of the date of this
report.
126. I recommend that the DHB:
a) Give feedback to HDC, within three months of the date of this
report, on the implementation of its new e-prescribing system.
b) Use this case as an anonymised case study for education for
paediatric medical staff, and report back to HDC on this within
three months of the date of this report.
127. I recommend that the pharmacy :
a) Undertake two audits of compliance with its Dispensing
Prescription SOP by taking two random selections of 30
prescriptions processed during a three-month period, and report
back to HDC on the results of these audits at three and six months
from the date of this report.
b) Use this case as an anonymised case study for education for
future pharmacist or pharmacy intern employees of the pharmacy.
128. I recommend that the Pharmacy Council of New Zealand
consider whether a review of Ms B's competence is warranted, and
report back to HDC with the results of any review.
129. I recommend that the Ministry of Health actively continue
to support the rollout of ePA across New Zealand's DHBs in both
inpatient and outpatient settings, and work with the sector to
progress an integrated approach to medicines management.
Follow-up actions
130. A copy of this report with details identifying the parties
removed, except the experts who advised on this case, will be sent
to the Medical Council of New Zealand, and it will be advised of Dr
C's name in covering correspondence.
131. A copy of this report with details identifying the parties
removed, except the experts who advised on this case, will be sent
to the Pharmacy Council of New Zealand, and it will be advised of
Ms B's and Ms D's names in covering correspondence.
132. A copy of this report with details identifying the parties
removed, except the experts who advised on this case, will be sent
to the Health Quality Safety Commission, the New Zealand
Pharmacovigilance Centre, the College of Education and Training
branch of the Pharmaceutical Society of New Zealand, and the
Paediatrics and Child Health Division of the Royal Australasian
College of Physicians, and placed on the Health and Disability
Commissioner website, www.hdc.org.nz, for educational purposes.
Appendix A: Independent
paediatric advice to the Commissioner
The following expert advice was obtained from consultant
paediatrician Dr Roger Tuck:
"My name is Roger Tuck and I am a consultant paediatrician
currently employed by the Northland District Health Board. I
obtained my basic medical degree from the University of London in
1972. I obtained Membership of the Royal College of Physicians (UK)
in 1974, Fellowship of the Royal Australasian College of Physicians
in 1981 and Fellowship of the Royal College of Physicians
(Edinburgh) in 1994. I have been a consultant general paediatrician
in New Zealand since 1983.
I have no personal or professional conflict of interest in
regard to this case.
As a general paediatrician, I have considerable experience with
renal and urological conditions of childhood and am familiar with
the surgical procedures described for this young child, and the
drugs used, particularly oxybutynin, the drug in question in this
case.
I have read the material provided by your office including the
guidelines for independent advisors which I will do my best to
follow.
Reasonableness of care provided by [Dr C]:
The information provided would suggest that with the exception
of the prescription error, the care provided both pre and
post-event was of a good standard. The prescription error, as with
all prescription errors, was unacceptable. It would appear that
this was a simple transcription error as there is evidence that [Dr
C] had taken care to calculate an appropriate dose of oxybutynin
for her patient. [Dr C's] subsequent response to this error was
prompt and professional including an approach to the family to
apologise. She has clearly reflected on this error and will
undoubtedly take measures to reduce the risk of further prescribing
errors in her own practice.
Digital prescribing/e prescribing:
As the Commissioner is aware, iatrogenic harm from prescription
and dispensing errors is one of the main causes of avoidable
morbidity and mortality in health systems worldwide. New Zealand is
no exception and as far as I am aware there is no active national
strategy on the implementation of standardised e prescribing in
DHBs throughout NZ, and certainly no significant implementation of
systems nationally. I am aware however that there are piecemeal
efforts in various DHBs. My own view is that a standardised
national system for electronic/digital prescribing throughout New
Zealand's health care settings is well overdue. In the meantime,
patients will continue to be at unnecessary risk of iatrogenic
medication related morbidity and mortality due to inevitable human
error and the risks of manual prescribing and dispensing.
Follow up actions:
This prescribing error was clearly taken seriously and
appropriate internal reviews took place. Basic issues such as
legibility, the use of decimal points and 'trailing zeros' have
been re-visited. Many of the risks of manual prescribing are open
to mitigation using digital systems. Ideally digital/e prescribing
should be available in all health care settings where prescribing
takes place. Algorithms can be embedded in such systems to aid
appropriate medication choices, avoid adverse medication effects
and interactions, and ensure appropriate dosages of
medications.
With particular respect to prescribing for children, a safety
and quality improvement that I am currently pursuing in my own DHB
is the addition of a box on the DHB prescription pad for the
patient's weight. I note that this is also absent from [the DHB's]
prescription pad. Many medications are prescribed on a dose per
weight basis in all age groups, but this is particularly important
in children where doses of medications should be routinely checked
on a dose per weight basis. The addition of a box on the
prescription pad for the patient's weight would provide both a
prompt for careful medication dose calculation and also provide an
important additional check for the dispensing pharmacy to minimise
the risk of inappropriate dosing in the context of manual
prescribing. A digital system could include a mandatory field for
weight.
Community Pharmacy:
I am aware that I have not been asked to comment on this, but I
would like to point out that as prescribing clinicians we rely on
our pharmacy colleagues both within hospital settings and in
community pharmacies to audit our prescriptions. … When [Miss A's]
medication was dispensed there should have been an opportunity to
check the appropriateness of the prescription.
Summary:
Prescribing and dispensing errors are unquestionably serious
departures from acceptable standards of care and can be responsible
for avoidable morbidity and mortality. In [Miss A's] case, had her
parent not been as vigilant and professionally knowledgeable, the
outcome could have been much worse. Technology, in the form of
digital or e prescribing, is available to mitigate the risks of
manual prescribing. Digital systems are in their infancy in NZ. In
the meantime, continuing education of clinical staff on manual
prescribing with continuing innovation to mitigate risks is
essential.
[Dr C's] error would appear to be a simple human error of
transcription. Her response to this was prompt and professional and
elicited the appropriate cascade of enquiry and reflection both
personally, and within the department of paediatric surgery at [the
hospital].
Fortunately in [Miss A's] case, the outcome was largely
favourable and my sympathies and best wishes go to her and to her
family for what must have been a very difficult and upsetting time.
My sympathies also go to [Dr C] as I am aware of the distress that
such an event can cause the involved clinicians.
Dr Roger Tuck. FRACP. FRCP. Consultant Paediatrician."
Appendix B: Independent pharmacy
advice to the Commissioner
The following expert advice was obtained from pharmacist
Sharynne Fordyce:
"I, Sharynne Fordyce, have been asked to provide an opinion to
the Commissioner on Case number C15HDC01542. I have read and agreed
to follow the Commissioner's Guidelines for Independent
Advisers.
My qualifications include a Diploma of Pharmacy, and a Masters
of Clinical Pharmacy. I have worked in Retail Pharmacy for over 30
years, both in New Zealand and in England, and also locum for the
Wairarapa DHB. I have also been involved in training and assessing
intern pharmacists.
Expert advice requested
Please review the enclosed documentation and advise whether you
consider the care provided to [Miss A] was reasonable in the
circumstances, and why. In particular, please comment on:
1. The reasonableness of the care provided by each of the
following:
a. [Ms B]
b. [Ms D]
c. [Ms E]
d. [The pharmacy]
2. In this case, who and/or which entity was responsible for
ensuring the correct dose of oxybutynin was dispensed for [Miss
A].
3. Who and/or which entity was responsible for ensuring the
dispensing prescriptions SOP was followed, in particular, that the
prescription was initialled/signed to identify the dispenser and
checker?
4. Was the dispensing prescriptions SOP, in place at the time of
these events, appropriate?
5. Are the changes made to the dispensing prescriptions SOP, in
light of these events, appropriate?
6. Were the other actions taken by the pharmacy and its staff,
following these events, appropriate?
7. Any other matters in this case that you consider warrant
comment.
For each question, it would be helpful if you would advise:
a. What is the standard of care/accepted practice?
b. If there has been a departure from the standard of care or
accepted practice, how significant a departure do you consider this
to be?
c. How would this be viewed by your peers?
d. Recommendations for improvement which may help prevent a
similar occurrence in future.
If you note that there are different versions of events in the
information provided, please provide your advice in the
alternative. For example: whether the care was appropriate based on
scenario (a), and whether it was appropriate based on scenario
(b).
Document copies provided
1. Letter of complaint dated […]
2. Prescription form dated 8 September 2015
3. Incident notification form dated 17 September 2015
4. Apology letter from [Ms B] dated 16 September 2015
5. [The pharmacy's] 'Dispensing Prescriptions' Standard
Operating Procedures (SOPs) (old and new)
6. [The pharmacy's] response and all enclosures dated 17 April
2016
7. [The pharmacy's] further response dated 13 May 2016
8. [Ms B's] response dated 7 April 2016
9. [Ms E] response dated 26 May 2016
Background summary
8 September 2015 a public hospital registrar wrote a
prescription for [Miss A] for, among other things 'Oxybutynin 20mg
TDS oral 10/7'.
8 September 2015 [Miss A's] father [Mr A] presented the
prescription to the pharmacy to be filled. [Ms B] was the only
pharmacist on duty at the time, working with [Ms E], intern
pharmacist. Oxybutynin and one other item were not in stock, could
be ordered for next day, father informed by [Ms B]. Rest of
prescription could be dispensed.
[Ms E] started to work on the prescription, generating a label
for oxybutynin. [Ms B] checked the label, which had been put
through for tablets instead of liquid. Noted also 'dose seemed
high', retyped label for liquid and put aside to await stock.
Discussed high dose of oxybutynin with father, who replied [Miss A]
had just come out of surgery. [Ms B] did not check dose
further.
9 September 2015, [Ms B] and [Ms D] on duty, [Ms E] on day off.
Oxybutynin liquid arrived, labelled and bagged for delivery. No
initials on prescription form for dispenser or checker. Delivered
that afternoon by [Ms D] to [Miss A's] mother, [Mrs A],
prescription not discussed.
12 September 2015 morning, mother administered 20ml of
oxybutynin liquid to [Miss A]. Concerned about large volume for
young child, internet search revealed overdose, rushed [Miss A] to
hospital.
12 September 2015, later in day [Ms D] received a telephone call
from a surgical registrar at the hospital, explaining what had
happened. [Ms D] sights script, and left a telephone message for
[Mrs A] apologising for error.
14 September 2015 all staff involved told of error.
15 September 2015 Pharmacy Defence Association (PDA) contacted
for advice.
16 September 2015 [the pharmacy] updated its dispensing
prescriptions SOP. [Ms B] wrote letter of apology to [Mr and Mrs
A].
17 September 2015 apology letter delivered to [Mr and Mrs A] and
[Ms B] filled in an incident notification form.
1 .STANDARD OF CARE PROVIDED
a) [Ms B]. Working from [the pharmacy's] training records, it
would appear that in 2015 [Ms B] was in her first year as a
registered pharmacist. On the day of the incident she was in sole
charge of an intern pharmacist, a person a year behind her in
training and experience. [Ms B] followed good prescription and
dispensing practices (in accordance with [the pharmacy's] SOP) by
keeping the customer informed of stock shortages, potential delays
and expected stock arrival time. She allowed [Ms E] to process the
prescription, part of an intern's training, and by [Ms B's] own
admission, helped [Ms E] with calculations she appeared unsure of.
When checking the labels produced by [Ms E] she noticed the mistake
with the dosage form of oxybutynin (tablets not liquid) and noted
the high dose, but did not confirm this dose with the prescriber.
The prescription was written by a registrar from [the hospital],
with the associated implications of specialist knowledge and
potentially unusual doses. Hospital doctors are frequently
difficult to locate, to do so can take hours and many phone calls.
However this dose of 20mg three times daily is three times the
maximum dose for an adult, and is not recommended for use in
children under 5 years of age. Therefore accepted practice would
have been to contact the prescriber and not to dispense the
medicine until the dose had been clarified. Not to have done so
would be viewed by myself and my peers as a serious departure from
the accepted standard of care. Receiving assurance from the father
re the 'high' dose is not sufficient. Depending on which pharmacist
checked and labelled the bottle of oxybutynin when it came in the
next day means either [Ms B] or [Ms D] missed another opportunity
to check the unusual dose. This behaviour is also at odds with the
2014 dispensing prescriptions SOP of [the pharmacy].
b) [Ms D], although not involved in the actual processing and
dispensing of the script on 8 September, was present in the
dispensary before it was handed out. She had been made aware of [Ms
B's] concern for [Ms E's] inability to independently complete the
calculations involved with the doses on the prescription. As [Ms
E's] preceptor, and the senior pharmacist present, good practice
would have suggested [Ms D] check the prescription, calculations
and labels, as she herself admitted later. It has been noted that
there is no completed training log for [Ms E] as regards knowledge
of SOPs. Not discussing the contents of the bag before handing over
the prescription is also a departure from good practice. As
the child had been in hospital, the parents were likely to be
distressed and may have been confused about drugs and doses. There
are no signatures on the prescription to indicate who processed,
dispensed or checked the prescription. This goes against the 2014
dispensing prescriptions SOP, and lack of identifying signatures
had also been noted on the otherwise excellent audit of [the
pharmacy]. With the volume of prescriptions being dispensed
nationally, accountability for every item dispensed is viewed as
extremely important by the profession.
c) [Ms E] was working as an intern pharmacist at [the pharmacy],
with [Ms D] as her preceptor, when this error occurred … All of
these tasks [entering the prescription into the computer, producing
labels, or completing any dosage calculations] should have been
within the capabilities of an intern. This does not agree with the
description of the incident by either [Ms B] or [Ms D]. Due to the
lack of identifying signatures on the prescription this discrepancy
is hard to solve. However there are annotations (calculations)
visible on the copy of the prescription which may be able to be
linked to either [Ms E] or [Ms B]. … At some stage after this
incident [Ms E] appears to have left the employ of [the pharmacy],
to finish her internship elsewhere. While there is no doubt that
full responsibility must lie with the qualified pharmacists
involved, all interns are trained to dispense each prescription as
if they were solely responsible for the final product, including
attention to dosages.
d) [The pharmacy], at the time of the incident, had in place
appropriate dispensing prescriptions SOPs. It had passed a Ministry
of Health Pharmacy Quality Audit 4 which evaluated procedures,
systems and processes, in September 2014. It employed legally
qualified staff and provided a wide range of services to the local
community. It was able to order in, supply stock and deliver
prescriptions within an appropriate time frame, thus providing an
acceptable standard of care.
2. In this case [Ms B] and [Ms D] were responsible for ensuring
the correct dose of oxybutynin was dispensed for [Miss A].
(Competence Standards for Pharmacy M1.2, O1.3.3, O1.3.4, O3.1.3 and
O3.1.4). The departure from the accepted standard of care was very
significant.
3. [Ms D], as the owner of [the pharmacy], is the person
primarily responsible for ensuring the dispensing prescriptions SOP
is communicated and followed, or the pharmacist on duty at the
time, being [Ms B]. All three women were responsible for
initialling or signing for the process they carried out, so as to
identify the processor, dispenser and checker. (Competence
Standards M1.2, O1.3.3, O1.3.4, O3.1.3 and O3.1.4). There has been
a considerable departure from acceptable practice in this
instance.
4. The dispensing prescriptions SOP, in place at the time of
these events, was entirely appropriate and adequate.
5. The changes made to the dispensing prescriptions SOP, in
light of these events, are very detailed, particularly in regards
to dosage calculations for children, and are appropriate.
6. The actions taken by [the pharmacy] and its staff, following
these events, were timely and appropriate. An earlier involvement
of the Pharmacy Defence Association may have been helpful, and
initiated an earlier filing of the incident notification form. This
may have potentially prevented minor discrepancies in the
pharmacists' reports.
The discrepancies in the recollection of events is
disconcerting. … That neither [Ms B] or [Ms D] could remember
whether or not [Ms E] was present at work on 9 September (her
regular day off for which she was not paid) is surprising. Also
unusual is that neither pharmacist could remember labelling,
checking and bagging the oxybutynin liquid, ready for delivery - a
significant departure from accepted practice. This later omission
denied both pharmacists the chance to investigate a significant and
harmful overdose."
Ms Fordyce provided the following further expert advice on 4
August 2016:
"Having read [Ms D's] reply to my comments I and all my peers
would very much agree with her regarding the need for shared blame
for consequences. As a profession, pharmacists accept that they are
the final barrier between any prescriber errors and the patient,
however both professions have a responsibility to ensure that there
are enough checks and balances in place to limit errors occurring
as much as possible.
In response to [Ms D's] comment regarding the structure of the
intern year and their assignments, I do have a reasonably good idea
of the programme involved. However I was unaware of [Ms E's]
progress through it as it can sometimes differ depending on the
intern and their circumstances. In light of [Ms D's] information I
would like to add the following sentences to my previous comments
on [Ms E].
By September [Ms E] would have been a significant way through
her internship, and only two and a half months away from undergoing
her final assessment for registration in November. Processing a
script such as [Miss A's], with a bit of supervision, should have
been within her capabilities, as should have been the calculations.
…
In summary, throughout the document I have been asked to comment
on how my peers would regard actions that were taken. I think,
almost without exception, my peers would regard this as a tragic
incident, both for [Miss A] and her family, and the pharmacists
involved. In spite of audits, SOPs, checks and balances, human
frailties will always be present."
Appendix C: Prescription
form
[Please refer to pdf version of this report for scanned
document]
District Health Board
Paediatric Registrar, Dr C
Pharmacy
Pharmacist, Ms B
Pharmacist, Ms D
A Report by the
Health and Disability Commissioner
(Case 15HDC01542)
Table of Contents
Executive summary 1
Complaint and investigation 3
Information gathered during investigation 4
Relevant professional standards 15
Opinion: Introduction 16
Opinion: Dr C - Breach 16
Opinion: DHB - Adverse comment 17
Opinion: Ms B - Breach 18
Opinion: Ms D - Breach 19
Opinion: Pharmacy - Breach 20
Opinion: Ms E - Adverse comment 21
Recommendations 22
Follow-up actions 22
Appendix A: Independent paediatric advice to the Commissioner
23
Appendix B: Independent pharmacy advice to the Commissioner
25
Appendix C: Prescription form 30
Executive summary
1. Miss A, aged two years and 11 months, experienced painful and
difficult urination following bladder surgery. She was reviewed for
this on 8 September 2015 by paediatric registrar Dr C at the Day
Stay Unit of a public hospital (the hospital). After discussion
with a senior colleague, Dr C prescribed some medications for Miss
A including oxybutynin, which is primarily indicated for the
management of urinary urgency and incontinence.
2. Dr C chose a dose of 2mg oxybutynin, "because [Miss A's] weight
was mid-range for her age, the dose is mid-range for dosage and 2mg
would be manageable for dispensing and administering". Instead of
writing "oxybutynin 2mg" three times daily for ten days on the
prescription form, Dr C wrote "oxybutynin 20mg", three times daily
for ten days, which was a ten times higher dose.
3. Miss A's father took the prescription forms to the pharmacy that
evening for the medications to be dispensed. Pharmacist Ms B
noticed that the oxybutynin dose seemed high but did not question
it at the time. The oxybutynin and one other item were not in
stock, so they were ordered for the next day.
4. The following day, the oxybutynin and the other item were
delivered to the pharmacy. Ms B and the pharmacy owner, pharmacist
Ms D, were on duty. The prescription forms are not initialled to
show who completed the dispensing. The medications were placed in a
bag, and the bag was placed in the delivery basket at the pharmacy.
Ms D delivered the medication to Miss A's mother. Ms D said that
she omitted to discuss the medication for Miss A with Miss A's
mother, but discussed a separate health issue.
5. Three days later, Miss A's mother gave Miss A the prescribed
dose of oxybutynin after she had ongoing pain with passing urine.
Miss A experienced side effects and was taken to the hospital's
Emergency Department, where she was monitored and discharged later
that day. Miss A experienced ongoing side effects.
Findings
6. It was Dr C's responsibility to ensure that she prescribed a
clinically appropriate dose of oxybutynin to Miss A. By failing to
do so, Dr C did not provide services with reasonable care and
skill, and the Commissioner found that she breached Right 4(1) of
the Code of Health and Disability Services Consumers' Rights (the
Code).
7. The Commissioner considered that if electronic prescribing had
been available to Dr C when she prescribed the medication to Miss
A, it could have minimised the risk of this error occurring.
8. Ms B failed to take steps to contact the prescriber when she
noticed that the oxybutynin dose seemed high. Ms B also did not
sign on the date stamp to indicate that she had dispensed and/or
checked Miss A's prescriptions in accordance with the pharmacy's
Dispensing Prescriptions Standard Operating Procedure (SOP). The
Commissioner found that Ms B did not provide Miss A with services
in accordance with professional standards, and breached Right 4(2)
of the Code.
9. The Commissioner was critical that Ms D did not check the
prescriptions, calculations and labels on 8 September 2015, did not
ensure that the Dispensing Prescriptions SOP was followed, and
missed an opportunity to check the appropriateness of the
prescription for Miss A at the time of delivery of the medications
to Miss A's mother. The Commissioner found that, in all the
circumstances, Ms D did not provide services to Miss A with
reasonable care and skill, and breached Right 4(1) of the
Code.
10. Non-compliance with the Dispensing Prescriptions SOP played a
part in Miss A receiving an inappropriate dose of oxybutynin.
Accordingly, the Commissioner found that the pharmacy did not
provide services to Miss A with reasonable care and skill and
breached Right 4(1) of the Code.
11. The Commissioner was critical that the pharmacy intern did not
sign the prescription to indicate her involvement in the dispensing
process.
Recommendations
12. The Commissioner recommended that Dr C, Ms B, Ms D and the
pharmacy each provide a written apology to Mr and Mrs A.
13. The Commissioner recommended that the DHB introduce systems to
allow a specific space for the recording of a child's weight on
prescriptions; give feedback to HDC on the implementation of its
new electronic prescribing system, and use this case as an
anonymised case study for education for paediatric medical
staff.
14. The Commissioner recommended that the pharmacy undertake two
audits of compliance with its Dispensing Prescription SOP, and use
this case as an anonymised case study for education for future
pharmacist or pharmacy intern employees of the pharmacy.
15. The Commissioner recommended that the Pharmacy Council of New
Zealand consider whether a review of Ms B's competence is
warranted.
16. The Commissioner recommended that the Ministry of Health
actively continue to support the rollout of electronic prescribing
across New Zealand's DHBs in both inpatient and outpatient
settings, and work with the sector to progress an integrated
approach to medicines management.
Complaint and investigation
17. The Commissioner received a complaint from Mrs A about the
services provided to her daughter, Miss A. The following issues
were identified for investigation:
• The appropriateness of the care provided to Miss A by Dr C in
September 2015.
• The appropriateness of the care provided to Miss A by the DHB in
September 2015.
• The appropriateness of the care provided to Miss A by the
pharmacy in September 2015.
• The appropriateness of the care provided to Miss A by Ms B in
September 2015.
• The appropriateness of the care provided to Miss A by Ms D in
September 2015.
18. An investigation was commenced on 31 March 2016.
19. The parties directly involved in the investigation were:
Mrs A Complainant/consumer's mother
District Health Board Provider
Pharmacy Provider
Ms B Pharmacist
Dr C Paediatric registrar
Ms D Pharmacist
Ms E Pharmacy intern
Also mentioned in this report:
Mr A Miss A's father
Dr F Paediatric surgeon
20. Information was also reviewed from:
The Medical Council of New Zealand
The Pharmacy Council of New Zealand
21. Independent expert advice was obtained from consultant
paediatrician Dr Roger Tuck (Appendix A) and pharmacist Sharynne
Fordyce (Appendix B).
Information gathered during investigation
Background
22. On 25 August 2015, Miss A, aged two years and 11 months, had an
operation by paediatric surgeon Dr F to remove a urachal cyst
from her bladder. Miss A was discharged the following day. A
urinary catheter was inserted during surgery and then removed three
days later. Miss A experienced worsening dysuria (painful/difficult
urination) following the catheter removal and was prescribed a dose
of oxybutynin that was too high for a toddler. This report is
about the care Miss A received in relation to the prescribing and
dispensing of oxybutynin in September 2015.
8 September 2015
Day Stay Unit
23. On 8 September 2015, Miss A was seen at the Day Stay Unit for
review of her dysuria by paediatric registrar Dr C.
24. Dr C examined Miss A and found that her abdomen was soft and
non-tender. Miss A had an ultrasound scan, which showed thickening
of the top of the bladder and a small volume of free fluid adjacent
to the bladder wall, which was likely a result of her recent
surgery. Dr C discussed Miss A's case with Dr F, and they decided
to start Miss A on a course of antibiotics, analgesia (pain
relief medication) and oxybutynin.
25. Dr C handwrote the prescriptions for Miss A on two separate DHB
prescription forms (see Appendix C). Regarding the oxybutynin
prescription, Dr C stated:
"I … split the analgesia onto a separate prescription sheet and
referred to the appropriate medication dose in the New Zealand
Formulary for Children (NZFC). I split the analgesia because
this is commonly prescribed and administered whereas the other
medication is less so and I wanted to reduce the risk of an error.
The dose range [for oxybutynin] for patients 2-5 years is
1.25-2.5mg and I chose 2.0mg because [Miss A's] weight was
mid-range for her age, the dose is mid-range for dosage and 2mg
would be manageable for dispensing and administering. I documented
the on-call contact number which is routine practice to enable
checking of the medication if there is a query about the medication
or dosage or frequency by either the pharmacy or parents. The
on-call phone is manned 24/7 by a surgical registrar."
26. Instead of writing "oxybutynin 2mg" three times daily for ten
days on the prescription form, Dr C wrote "oxybutynin 20mg", three
times daily for ten days, which was a ten times higher dose. Dr C
also documented Miss A's weight, 14kg, on both prescription forms.
Dr C later told HDC that "the prescription read 20mg rather than
2.0mg".
27. The DHB confirmed that Dr C received an orientation booklet as
part of her registrar training, which included guidelines on safe
prescribing and links to the hospital's prescribing guidelines. The
hospital's prescribing guidelines state: "Never write a trailing
zero after a whole number ie 8mg, not 8.0mg."
28. Miss A was discharged with a plan to review her in one week's
time (on 15 September 2015) at the registrar clinic.
The pharmacy
29. Miss A's father, Mr A, took the prescriptions to the pharmacy
at around 5pm on 8 September 2015 for the medications to be
dispensed. Ms B was the pharmacist on duty and was working
with pharmacy intern Ms E.
30. Ms B said that Ms E took the prescriptions from Mr A and began
processing them through the computer. Ms E told HDC that she does
not recall whether she entered the prescriptions into the computer,
but does recall being involved in the dispensing of some
medications for Miss A that were in stock.
31. Ms B said that she informed Mr A that the oxybutynin and the
lignocaine gel were not in stock and could be ordered for the next
day, but that the rest of the medications could be dispensed at
that time.
32. Ms B said that Ms E began working on dispensing the
medications. Ms B stated: "I had to help [Ms E] calculate the
volume required for the doses of Augmentin, Paracetamol, Ibuprofen
and Tramadol, because she was struggling to convert the
[milligrams] on the prescription to [millilitres] required for
dosing." Ms B stated that she reconstituted the antibiotic
suspension while Ms E dispensed the other items on the
prescription.
33. Ms B told HDC that, as she was checking the medication labels,
she noticed that oxybutynin had been entered into the computer as
tablets, rather than as the liquid that had been prescribed. Ms B
told HDC that she "noticed that the dose seemed high, but did not
question it at the time". Ms B stated: "I acknowledge that I should
have attempted to contact the prescriber regarding the high dose of
oxybutynin at that time instead of leaving it for later, regardless
of what time of day it was."
34. Ms B generated a new oxybutynin label to read a liquid
formulation and put it to one side with the prescriptions, to
complete the dispensing when the new stock arrived the next day. Ms
B then ordered the oxybutynin and the lignocaine gel.
35. Pharmacy owner and pharmacist Ms D told HDC that she was out of
the pharmacy on 8 September 2015 when the prescription was
received, but that she arrived back at around 5.30pm, just as the
last of the in stock medications for Miss A were being dispensed.
Ms D said that she helped by dealing with other prescriptions that
were waiting to be completed, so that Ms B and Ms E could
concentrate on Miss A's prescriptions.
36. Ms D said that, after the medications were given to Mr A, Ms B
expressed frustration to her regarding Ms E's inability to
calculate the volumes required accurately. Ms D stated: "In
hindsight, this should have been my [c]ue to check the entire
prescription but I didn't." Ms D also told HDC: "I have faith in
[Ms B's] capabilities that she would have corrected any errors. At
the time I had no need to double check her work."
37. The prescriptions for Miss A's medications are not initialled
or signed to show who carried out the dispensing or checking.
However, there are some annotations on the prescriptions. Ms D
advised HDC that these are mainly written by Ms B, but that some
had been written and scribbled out by Ms E. Ms D stated that often
Ms E wrote calculations on scrap bits of paper and discarded them,
rather than annotating them on the prescription as instructed,
"mak[ing] it very difficult to prove who did what on the
prescription". Ms D stated that the annotations by Ms B indicate
that she had to take over because Ms E was unable to do the
calculations.
9 September 2015
38. On 9 September 2015, Ms B and Ms D were the pharmacists on duty
at the pharmacy, and there was also a pharmacy student present. Ms
E was not working, as it was her regular day off.
39. The oxybutynin liquid and lignocaine gel were delivered to the
pharmacy at around 11am. The medications were then labelled and
bagged for delivery. However, the prescriptions are not initialled
or signed to show who dispensed or checked these items. Ms B and Ms
D both told HDC that they are unsure who completed the dispensing
by labelling and bagging the medications, and whether a final check
was carried out. Ms D stated: "As there are no signatures on the
prescription for the dispensing of this item, as the owner I will
take responsibility as it was either [Ms B] or myself, we just
cannot be certain."
40. The bag of medications was placed in the delivery basket at the
pharmacy. That afternoon, Ms D delivered the medications to Miss
A's mother, Mrs A. Mrs A told HDC that the medications were
delivered to her house in a brown bag. She stated:
"[The pharmacist] knew I had two very sick kids so I think they
were saving me a trip back with one vomiting baby and one toddler
beside herself in pain after having bladder surgery. I asked the
pharmacist about the oxybutynin and she said they very rarely use
it, that it can cause sedation."
41. Ms D stated that she "chatted with [Mrs A] in regards to a
separate health issue concerning her other daughter … At no point
did I discuss the prescription for [Miss A]." Ms D said that, while
she omitted to discuss the medication for Miss A, she told Mrs A
that if she had any questions she could call her or Ms B at any
time.
12 September 2015
42. On the morning of 12 September 2015, Mrs A administered Miss A
20ml of oxybutynin. Mrs A told HDC that she was nervous about using
the oxybutynin, and that she recalls having the medication for a
few days before she gave it to Miss A.
43. Mrs A stated:
"As soon as I gave it, I thought that is an awful lot of medicine
to get in to a child. I […] quickly googled, and discovered that
this was an almost TEN TIMES overdose of a very dangerous drug. I
rushed her to [the hospital] which is 15 minutes from my house. By
the time I got there, she was blind from dilated pupils, was
hallucinating and was starting to slur her words."
44. Miss A was reviewed in the Emergency Department (ED) at 8.10am
by a paediatric registrar, who recorded on the discharge
summary:
"Almost 3 year old girl presents after taking a 7 x the standard
dose of oxybutynin at home as per the prescription. This equates to
1.4mg/kg (normal dose is 0.2mg/kg). Mother feels that [Miss A is]
finding it difficult to see looking at toast closely, pupils
dilated. Starting to sway. Not her normal self … [Miss A] has
ongoing pain with passing urine last night. Therefore, mother gave
oxybutynin this morning."
45. The paediatric registrar examined Miss A and noted that her
heart rate was 126 beats per minute, her respiration rate was 30
breaths per minute, her oxygen saturation was 100%, her temperature
was 37.3°C, and her blood sugar level was 5.1mmol/L. These
observations are all within the normal range for a child of Miss
A's age.
46. The paediatric registrar's impression was that Miss A had some
signs of mild anticholinergic toxicity. Miss A had initial
and repeat electrocardiograms, which were normal.
47. Mrs A told HDC that Miss A had tremors and jerky movements, was
sedated and difficult to rouse, she could not speak, and she had a
high heart rate.
48. At 1.30pm, Miss A was reviewed by a paediatric surgical
registrar, who recorded that he would follow up with the
pharmacy and prescriber to find out how the error had happened, to
stop it happening again.
49. Ms D told HDC that she was contacted by the registrar, who told
her what had happened. Ms D said that she then left a telephone
message for Mrs A apologising for the error.
50. It is documented in the clinical notes that Miss A had
myoclonic jerks while she was asleep in the ED that
afternoon. Miss A was discharged from the ED at around 5pm. The
discharge summary states that Miss A was alert and comfortable at
rest and had bilaterally dilated pupils. The discharge advice was
to continue taking the appropriate dose of oxybutynin the next day
if required (2.8ml three times daily or as needed) and to
return for review if Miss A had any abnormal behaviour, vomiting,
urinary retention, or worsening vision, or if her parents were at
all concerned.
13-15 September 2015
51. Dr C told HDC that, on 13 September 2015, the registrar told
her about Miss A's admission to the ED the previous day, and that
the registrar had contacted the pharmacy, had a photocopy of the
prescription emailed from the pharmacy to the ED, and had alerted
Dr F to the error. Dr C said that she discussed her error with the
Clinical Director of Paediatric Surgery on Monday 14 September
2015.
52. Ms D told HDC that, on 14 September 2015, all pharmacy staff
involved in the dispensing of Miss A's prescriptions convened to
discuss what had happened and establish how the error had occurred,
and to discuss how to prevent further incidents such as this
occurring.
53. On 15 September 2015, Dr C reviewed Miss A with Mrs A at the
registrar clinic, as had been arranged previously. Dr C said that
she apologised for the error at this time, and that Mrs A was
understandably very upset.
Subsequent events
54. Mrs A told HDC that Miss A had the following side effects after
the overdose of oxybutynin: several days of lethargy; confusion and
slurring her words; four days of severe abdominal pain,
restlessness and difficulty urinating; two weeks of low grade
fever; three days later, vomiting; and, four weeks later, bleeding
from her rectum. Mrs A was also concerned that the overdose caused
slow healing at Miss A's bladder surgery site, and urinary
retention. Miss A was seen for those issues in the ED on 17
September, 28 September, and 4 October 2015.
Further information - the pharmacy
Apology letter
55. On 16 September 2015, Ms B wrote a letter of apology to Mr and
Mrs A, which stated:
"As a pharmacist, it was my responsibility to query the high dose
of oxybutynin that was on the prescription and I failed to do
that.
As a result of this incident, we have reviewed our dispensing
procedures to ensure that similar mistakes won't happen to you or
anyone else in the future …
Once again I am very sorry that this occurred and offer my humble
apologies for the distress and inconvenience caused. I would like
to offer to pay for any ambulance fees or medical expenses that
were incurred as a direct result of my error."
Incident Notification form
56. On 17 September 2015, Ms B filled in an Incident Notification
form. She recorded that Mrs A contacted her on 13 September 2015 to
inform her of the error. The Incident Report form states:
"Details of the incident [Prescription] from hospital with lots of
doses to be calculated. Oxybutynin dose written as 20mg [three
times daily for ten days]. I noticed the dose was high but didn't
check it. The stock needed to be ordered so was dropped off by [Ms
D] on the 9th Sep. The first dose was given on the 11th Sep and
[Miss A] experienced anticholinergic [side effects] so was taken to
hospital. [Mrs A] called the pharmacy on Sunday to notify [Ms D] of
what had happened …
Action requested by customer Letter of apology and review
processes. Contact registrar that was responsible at
hospital.
Action taken by pharmacy after the event and by whom … [Ms D] and
[Ms B] went through the dispensing SOP and updated the procedures
relating to suspensions and child doses. Wrote a letter of apology
…
Investigation of incident … Pharmacy was busy -> 3
[prescriptions] happening at the same time. [Prescription] had 6
doses that needed calculating. Intern made an error when processing
[prescription] -> tablets rather than suspension. Dose was not
checked / discharge summary was not looked at.
Outcome: correction action taken … Letter of apology written and
given to parents. SOP updated."
Dispensing Prescriptions Standard Operating Procedure (SOP)
57. The Dispensing Prescriptions SOP (issue date 7 March 2014) in
place at the time of the error stated:
"Purpose: To describe the process of dispensing in this pharmacy to
ensure that prescriptions are dispensed accurately and in
accordance with legislative and ethical requirements …
Checking Procedures
During dispensing process: …
• Check medicine dose, frequency interactions and
contraindications, to ensure the medicine is being given
appropriately (e.g. correct dose for age or condition) …
• Dispenser and checker must be identified on all prescriptions and
original dispensing, by signing on the date stamp …
Handing out procedures / Giving advice to customers
• It is the sole responsibility of the pharmacist to hand out
prescriptions, or delegate this task ensuring that the necessary
information and counselling is given to the patient."
58. The SOP was updated on 16 September 2015 to include the
following section on calculations for child doses:
"Calculations for child doses
• Write out the full calculation on the prescription so that it can
be checked at each step of dispensing.
Dose (ml) = Dose (mg)
X mg/kg = X mg/dose
X mg/dose = X ml/dose
• If no weight is available for the child, calculate the expected
weight for the prescribed dose and leave a 'check weight' label
with the medication.
• Check that the dose is appropriate for the child's weight and age
according to the Paediatric Pharmacopoeia or NZF.
• If the dose is low or high, notify the pharmacist on duty to deal
with it appropriately."
Ms D
59. Ms D stated that "the prescriber should have been contacted and
[oxybutynin] not dispensed until this could occur and the dose been
discussed". She told HDC:
"I must remind all pharmacists that clinical checks need to be done
on every prescription to ensure the dose is appropriate for the
patient. This was a prescribing error that was not picked up, and
as pharmacists we are responsible for the last check."
60. Ms D told HDC: "I cannot explain why the prescriptions were not
initialled as being dispensed and checked, as this is part of the
pharmacy SOPs. I admit that we had not been very good at making
people accountable for this, but we are now." Ms D acknowledged
that as the owner and director of the pharmacy, it is her
responsibility to ensure that all dispensary staff follow the SOPs
in place.
61. Ms D stated that she continues to monitor all dispensary staff
to ensure they follow the SOPs in place at the pharmacy, and that
staff are more diligent in ensuring that all prescriptions are
initialled by the dispenser and checker, and that all calculations
are recorded on the prescriptions, rather than on scrap bits of
paper. Ms D said that, in future, she will undertake random checks
on prescriptions dispensed to ensure that the pharmacy SOPs are
being followed.
62. In September 2014, the pharmacy had undergone a quality audit
for the Ministry of Health. The audit found that many of the
pharmacy's prescriptions did not include the name of the pharmacist
responsible for the final check for completeness and accuracy.
Following the audit, Ms D had confirmed in writing to the auditor
that "all prescriptions, including repeats and owes, will be
initialled by the checking pharmacist". Following this confirmation
(and clarification of some other matters), all audit criteria were
fully attained on 24 November 2014.
Further information - Ms B
63. Ms B told HDC that she has been involved in reviewing the
Dispensing Prescriptions SOP, has become much more cautious in her
dispensing, has improved her practice regarding initialling
prescriptions, makes sure that she calculates the exact dose by
weight for prescriptions for children, asks to read any discharge
summary available to ensure it aligns with the prescription, and
writes out all calculations in full on the prescription. She stated
that the pharmacy has placed a list of the usual doses that require
calculation next to the dispensing computer to make it easier
to check doses, now keeps the paediatric pharmacopoeia on
hand for other doses, and has "check weight" and "check dose"
labels to put with prescriptions where the weight is listed on the
prescription.
64. Ms B told HDC:
"The incident … has made us all strive to improve our pharmacy
practice and communication with each other. I am so incredibly
sorry that this happened and I'm doing everything I can to ensure
that I don't do it again."
Subsequent events - Dr C
65. Dr C told HDC: "I would like to apologise again for [the]
distress that this has caused [Miss A] and her family."
66. Dr C told HDC that she raised the error through her
department's morbidity and mortality meeting, and it was discussed
as a team. She stated:
"There was discussion regarding contributory factors; ensuring
safeguards are reviewed and the whole team learns from the mistake
to minimise the risk of this incident occurring in future.
The following points were discussed as learning points which I have
put into practice:
1. Trailing zeros - I don't usually use trailing zeros, but I
believe I did in this case because the range as specified in the
NZFC had fractions of a mg in each case with a decimal point in
each dose (eg. 1.25 and 2.5mg).
2. Using digital prescribing where possible - currently, there are
2 systems of prescribing - a paper system and a digital system. I
previously used the 2 interchangeably, but in an effort to ensure
accuracy, I will use the digital system in future. However, this is
not possible in the outpatient clinic due to the way the computer
system is set up. The electronic prescription system does require
the weight of a patient to be manually written after printing as it
is not currently considered essential when prescribing.
3. Re-review the prescriptions before handing them to
patients.
4. Continue to refer to prescription guides e.g. NZFC.
5. Continue to include a contact telephone number and patient's
weight on prescriptions to facilitate checking.
Once again, I was deeply saddened by [Miss A's] experience; it has
provided me with invaluable education for my future. I will do
everything possible in future to ensure this situation is not
repeated."
67. Dr C also told HDC that she has carried out a literature review
on medical error, which emphasised the importance of optimising the
prescribing environment, checking mechanisms and improving systemic
factors to reduce error. She stated that she has since avoided
prescribing in noisy or busy environments, printed prescription
guidelines and placed them in medication charts, encouraged an open
dialogue with nursing staff, become more engaged with the Riskpro
risk alert system, and progressed her active involvement with
hospital audits.
68. In May 2016, a senior pharmacist from the DHB audited Dr C's
prescribing while Dr C was working in the Neonatal Intensive Care
Unit. She reviewed 51 of Dr C's prescriptions over the period of
two weeks and, without exception, found these to be clinically
appropriate, legible, legally complete, and in accordance with
standard prescribing practice and relevant protocols. The
pharmacist told HDC that she discussed safe prescribing practices
with Dr C, and stated:
"[I] am confident that she has a good understanding of the
importance of prescribing legibly and completely, minimising
distractions during prescribing, and utilising appropriate dosing
resources for the clinical situation, as well as being aware of the
availability of various prescribing resources."
Subsequent events - the DHB
69. The Clinical Director of Paediatric Surgery told HDC:
"On behalf of our department, I too apologise to the family for
this error occurring. We recognise[d] the seriousness of the error
at the time and as a result, the following actions were
taken:
1. [Dr C] self-reported this error promptly through our
departmental morbidity review processes.
2. We have addressed the error through rigorous peer review in our
department and agreed with [Dr C's] actions, as outlined
above.
3. We are confident that this does not represent a systemic problem
or an educational omission in registrar training.
4. This incident provided us with the opportunity to discuss and
reflect on safe prescribing practices. We have ensured that all
members of our team know where to access prescribing information
and advice. However, this was not an issue in this case.
5. We have activated a Riskpro so the incident can be reviewed …
with our departmental protocols.
6. We are satisfied that [Dr C] has learned from this event
including discussion through the Morbidity and Mortality process.
This event has highlighted to all members of our medical team, the
critical importance of accurate prescribing using accepted
methodologies and terminology and the consequences of inattention
to detail."
70. The DHB agreed with HDC's expert advisor that having a space to
document the weight of a child on outpatient prescriptions would be
a useful addition for safety. In the provisional opinion, I
recommended the DHB introduce systems to allow a specific space for
the recording of a child's weight on prescriptions. In response to
the provisional opinion, the DHB advised that it has now amended
its prescription form to include a space to document the weight of
a child under 13 years of age.
71. The DHB's electronic prescribing and administration (ePA)
programme started being introduced from mid-2016 to cover both
inpatient and outpatient prescribing. the DHB advised that the
MedChart ePA system has now been implemented on two wards,
and a project plan for further roll-out of ePA is being developed,
aligned to the Electronic Health Record strategy (to implement a
single electronic health record for the whole region and
sector).
72. The DHB has since introduced a paediatric prescribing memory
aid in the form of a safe prescribing reference card, which is
given to all house surgeons and registrars. This is a small card
that is clipped in with identity and swipe cards. It states:
"Right patient correct sticker on all pages AND clearly written
name and weight
Right medicine document generic name … LEGIBLY
Right dose and route calculate per kg (or m²) - sensible rounding,
don't exceed adult dose … document mg/kg dose for ease of
checking
Right time indication for [as needed] meds, date/time for once-only
meds, consider dose interval …
Identify yourself! Signature + surname + date when starting AND
ceasing medicines …"
The back of the card then directs staff to websites for resources
for prescribing in children.
73. The DHB told HDC that it is developing its clinical excellence
and safe care programmes to ensure that minutes are taken at its
morbidity and mortality meetings, and the learnings from
adverse events are disseminated throughout the DHB.
Further information - electronic prescribing
74. In the Ministry of Health's National Health IT Plan Update
2013/14 it specified that all DHBs were expected to have electronic
prescribing and administration (ePA) in place by 2016, and a
national contract has been signed that supports a standardised
approach to implementing electronic prescribing. Nine of New
Zealand's 20 DHBs have implemented, or are in the process of
implementing, ePA.
75. The Ministry of Health told HDC that the ePA system, MedChart,
is currently being enhanced to enable its use in outpatient
settings, and this will be available for early adopter testing in
early 2017. Following the successful early adopter testing in
outpatient settings, the Ministry of Health said that it will
continue to work with DHBs to progress the rollout of ePA across
hospital inpatient and outpatient settings. The Ministry of Health
stated that it is also working with the sector (hospital and
community) to develop a more integrated approach to medicines
management across the New Zealand health system.
Responses to the provisional opinion
76. Responses to the provisional opinion were received from all
parties, and a response to the "information gathered during
investigation" section of the provisional opinion was received from
Mrs A. Where appropriate, responses have been incorporated into the
"information gathered during investigation" section
above.
77. Ms B, Ms D, the pharmacy and Ms E confirmed that they had no
comments in response to the provisional opinion.
78. Dr C confirmed that she would write a letter of apology to the
family as recommended. She also stated that she continues to
maintain heightened levels of vigilance over her practice, and uses
the digital prescribing system at the DHB where
possible.
79. The DHB confirmed that it would advise HDC of further actions
undertaken in due course.
80. Mrs A told HDC that, following the overdose, Miss A struggled
to urinate for days and would scream in pain for hours at a time
without being able to sleep or eat much. Mrs A said that it took
Miss A three to four months to be able to urinate properly, and
that she had been doing reasonably well up until the overdose. Mrs
A is concerned that Miss A may now have autonomic dysfunction
as a result of the medication reactions.
Relevant professional standards
81. The Pharmacy Council of New Zealand (PCNZ) Competence Standards
for the Pharmacy Profession (2015) state:
"M1.2 Comply with ethical and legal requirements …
O1.3.3 Uses professional judgement to determine whether changes to
the medication treatment regimen are needed to improve safety,
efficacy or adherence
O1.3.4 Liaises with and provides recommendations to the prescriber
and/or the other healthcare professionals to ensure optimal use of
medicines by patients …
O3.1.3 Applies knowledge in undertaking a clinical assessment of
the prescription to ensure pharmaceutical and therapeutic
appropriateness of the treatment and to determine whether any
changes in prescribed medicines are warranted
O3.1.4 Initiates action, in consultation with patient/carer and/or
prescriber to address identified issues."
82. The PCNZ Code of Ethics (2011) states:
"1.2 Take appropriate steps to prevent harm to the patient and
public …
5.1 Be accountable for practising safely and maintain and
demonstrate professional competence relative to your sphere of
activity and scope of practice."
Opinion: Introduction
83. This case is an unfortunate example of errors occurring in
tertiary hospital outpatient clinic and community pharmacy
settings, which allowed for a child to be administered medication
in a dose that was clinically unsafe.
84. It is essential that all providers involved in the prescribing
and dispensing of medication remain attentive to the possibility of
errors occurring at different steps in the process. Providers must
take great care to ensure they have performed their role in the
process accurately.
Opinion: Dr C - Breach
85. Under Right 4(1) of the Code, Miss A had the right to have
services provided by Dr C with reasonable care and
skill.
86. On 8 September 2015, after discussing Miss A's case with Dr F,
Dr C handwrote Miss A's prescriptions on two prescription forms. Dr
C explained that she wrote the oxybutynin prescription on a
separate form because it is less commonly prescribed than the other
medications. Dr C told HDC that she referred to the appropriate
medication dose in the NZFC and that she chose a 2mg dose because
"[Miss A's] weight was mid-range for her age, the dose is mid-range
for dosage and 2mg would be manageable for dispensing and
administering".
87. Instead of writing "oxybutynin 2mg" on the prescription form,
Dr C wrote "oxybutynin 20mg" - a ten times higher dose. Dr C also
documented Miss A's weight, 14kg, on both prescription forms. Dr C
told HDC that she does not usually use trailing zeros (eg, 2.0mg
instead of 2mg), but believes she did in this case because the
range as specified in the NZFC had fractions of a milligram with a
decimal point in each dose (eg, 1.25 and 2.5mg). Dr C later told
HDC that "the prescription read 20mg rather than 2.0mg".
88. The DHB confirmed that Dr C received an orientation booklet as
part of her registrar training, which included guidelines on safe
prescribing and links to the prescribing guidelines. The
prescribing guidelines state: "Never write a trailing zero after a
whole number ie 8mg, not 8.0mg." Despite Dr C's explanation, I am
concerned that she did not follow the prescribing guidelines
regarding trailing zeros in this case.
89. I am satisfied that Dr C's error was a transcribing error that
occurred when she wrote the dose on the prescription form, as she
had taken steps to choose a clinically appropriate dose.
Nevertheless, Dr C recorded on the prescription form a dose that
was significantly higher than recommended for a child of Miss A's
age and weight. My expert advisor, paediatrician Dr Roger Tuck,
advised:
"The prescription error, as with all prescription errors, was
unacceptable … prescribing and dispensing errors are unquestionably
serious departures from acceptable standards of care."
90. I accept Dr Tuck's advice. It was Dr C's responsibility to
ensure that she prescribed a clinically appropriate dose of
oxybutynin to Miss A. By failing to do so, she did not provide
services with reasonable care and skill and breached Right 4(1) of
the Code.
91. I consider that, once Dr C was aware that the error had
occurred, she took appropriate steps to disclose it and to minimise
the risk of such an error occurring again.
Opinion: DHB - Adverse comment
92. At the time of these events, Dr C was an employee of the DHB.
In addition to any direct responsibility for a breach of the Code,
under section 72(2) of the Act, employers are responsible for
ensuring that their employees comply with the Code. Pursuant to
section 72(5) of the Act, it is a defence for an employing
authority to prove that it took such steps as were reasonably
practicable to prevent the acts or omissions leading to an
employee's breach of the Code.
93. At the time of these events, electronic prescribing was
available at the DHB but not in the outpatient clinic setting. I
consider that, if electronic prescribing had been available to Dr C
when she prescribed the medication to Miss A in the Day Stay Unit,
it could have minimised the risk of this error
occurring.
94. The DHB confirmed that Dr C received an orientation booklet as
part of her registrar training, which included guidelines on safe
prescribing and links to the prescribing guidelines. Accordingly, I
do not consider that this error represents a failure with regard to
orientation or training provided to Dr C. I am satisfied that the
error in failing to prescribe a clinically appropriate dose of
oxybutynin to Miss A was Dr C's alone, given that she had taken
steps to choose a clinically appropriate dose, but failed to
transcribe this accurately.
95. My expert advisor, paediatrician Dr Roger Tuck, advised:
"Digital systems are in their infancy in NZ. In the meantime,
continuing education of clinical staff on manual prescribing with
continuing innovation to mitigate risks is essential."
96. The DHB told HDC that its new e-prescribing programme, which is
being introduced from mid-2016, will cover both inpatient and
outpatient prescribing. I consider it both necessary and
appropriate that this is being introduced. The DHB has advised that
it has also introduced a paediatric prescribing memory aid in the
form of a safe prescribing reference card, which is given to all
house surgeons and registrars. I am satisfied that the actions
taken by the DHB following the error are appropriate in the
circumstances.
Opinion: Ms B - Breach
97. As a registered pharmacist, Ms B is responsible for ensuring
her adherence to professional standards. The PCNZ competence
standards require that a registered pharmacist "[a]pplies knowledge
in undertaking a clinical assessment of the prescription to ensure
pharmaceutical and therapeutic appropriateness of the treatment and
to determine whether any changes in prescribed medicines are
warranted". The PCNZ Code of Ethics requires registered pharmacists
to be accountable for practising safely and for maintaining and
demonstrating professional competence.
98. The Pharmacy Dispensing Prescriptions SOP required Ms B to:
"Check medicine dose, frequency interactions and contraindications,
to ensure the medicine is being given appropriately (eg. Correct
dose for age or condition)."
99. Ms B was the pharmacist on duty on 8 September 2015, and was
working with pharmacy intern Ms E. Ms B told HDC that, as she was
checking the medication labels for Miss A's prescriptions on 8
September 2015, she "noticed the dose [of oxybutynin] seemed high,
but did not question it at the time". Ms B stated: "I acknowledge
that I should have attempted to contact the prescriber regarding
the high dose of oxybutynin at that time instead of leaving it for
later, regardless of what time of day it was." Ms B put the
oxybutynin label to one side with the prescription, to complete the
dispensing when the new stock arrived the next day.
100. My expert advisor, pharmacist Sharynne Fordyce, advised:
"This dose of 20mg three times daily is three times the maximum
dose for an adult, and is not recommended for use in children under
5 years of age. Therefore accepted practice would have been to
contact the prescriber and not to dispense the medicine until the
dose had been clarified. Not to have done so would be viewed by
myself and my peers as a serious departure from the accepted
standard of care."
101. I accept Dr Fordyce's advice. I am particularly concerned
that, despite Ms B noticing that the oxybutynin dose seemed high
for a child Miss A's age, she did not take steps to contact the
prescriber as required by the PCNZ Competence Standards for the
Pharmacy Profession and the Pharmacy's Dispensing Prescriptions
SOP.
102. The prescriptions for Miss A's medications are not initialled
or signed to show who carried out the dispensing or checking. The
Dispensing Prescriptions SOP required Ms B to sign on the date
stamp to indicate whether she dispensed and/or checked the
prescription. I am critical that she did not do so.
103. Ms B was one of two pharmacists working at the pharmacy on 9
September 2015 when the oxybutynin stock arrived at the pharmacy
and was labelled and bagged for delivery. Given that there are no
signatures on the prescription to indicate who completed the
dispensing or carried out the final check, and neither Ms B nor Ms
D can recall who did this, I am unable to make a finding as to
whether Ms B completed the dispensing of this prescription or
carried out the final check.
104. In conclusion, Ms B failed to take steps to contact the
prescriber when she noticed that the oxybutynin dose seemed high,
as required by the PCNZ Competence Standards for the Pharmacy
Profession and the pharmacy's Dispensing Prescriptions SOP. Ms B
also did not sign on the date stamp to indicate that she had
dispensed and/or checked Miss A's prescriptions on 8 September 2015
in accordance with the pharmacy's Dispensing Prescriptions SOP.
Accordingly, I consider that Ms B did not provide Miss A with
services in accordance with professional standards, and breached
Right 4(2) of the Code.
Opinion: Ms D - Breach
105. On 8 September 2015, Ms D arrived back at the pharmacy as the
last of the in stock medications were being dispensed for Miss A.
Ms D said that, after the medications were given to Mr A, Ms B
expressed frustration to her regarding Ms E's inability to
calculate the volumes required accurately. Ms D stated: "In
hindsight, this should have been my [c]ue to check the entire
prescription but I didn't."
106. My expert advisor, pharmacist Sharynne Fordyce, advised:
"[Ms D] had been made aware of [Ms B's] concern for [Ms E's]
inability to independently complete the calculations involved with
the doses on the prescription. As [Ms E's] preceptor, and the
senior pharmacist present, good practice would have suggested [Ms
D] check the prescription, calculations and labels, as she herself
admitted later."
107. In the circumstances, I am critical that Ms D did not check
the prescriptions, calculations and labels on 8 September
2015.
108. Ms D was one of two pharmacists working at the pharmacy on 9
September 2015 (the other was Ms B) when the oxybutynin stock
arrived at the pharmacy and was labelled and bagged for delivery.
There was also a pharmacy student working at the pharmacy that day.
Given that there are no signatures on the prescription to indicate
who completed the dispensing or carried out the final check, and
neither Ms D nor Ms B can recall who did this, I am unable to make
a finding as to whether Ms D completed the dispensing of this
prescription or carried out the final check. I am critical that, as
the owner and director of the pharmacy, Ms D did not ensure that
the Dispensing Prescriptions SOP was followed in this
regard.
109. The oxybutynin and lignocaine gel were put aside in a bag for
delivery and, on the afternoon of 9 September 2015, Ms D delivered
the medications to Miss A's mother, Mrs A. Mrs A told HDC that the
medications were delivered to her house in a brown bag. She
stated:
"[The pharmacist] knew I had two very sick kids so I think they
were saving me a trip back with one vomiting baby and one toddler
beside herself in pain after having bladder surgery. I asked the
pharmacist about the oxybutynin and she said they very rarely use
it, that it can cause sedation."
110. However, Ms D said that she "chatted with [Mrs A] in regards
to a separate health issue concerning her other daughter". Ms D
stated: "[A]t no point did I discuss the prescription for [Miss
A]." Ms D said that she told Mrs A that if she had any questions
she could call Ms D or Ms B at any time.
111. I note Dr Fordyce's advice:
"Not discussing the contents of the bag before handing over the
prescription is … a departure from good practice … I would consider
this departure to be a moderate to severe one as it was another
lost chance to check the dose, and talk to the
parents."
112. In my view, the discussion on delivery of the medications to
Mrs A was a missed opportunity for Ms D to check the
appropriateness of the prescription for Miss A, and I am critical
that she did not do so.
113. Accordingly, in the circumstances, I find that Ms D did not
provide services to Miss A with reasonable care and skill, and
breached Right 4(1) of the Code.
Opinion: Pharmacy - Breach
114. The pharmacy was responsible for ensuring that the pharmacy
provided services to Miss A with reasonable care and skill. This
includes the need to ensure staff compliance with its SOPs.
Pharmacies are responsible for the operation of services provided
by their staff, and can be held responsible for individual failures
by staff. While the individual pharmacists in this case also bear
responsibility for the deficiencies in the care provided to Miss A,
I am of the view that the deficiencies were also a result of issues
at the pharmacy.
115. Consumer safety is of the utmost importance, and I consider
that it is the responsibility of the pharmacy to ensure that every
staff member complies with its SOPs, in order to prevent harm to
patients. PCNZ, in its document "Writing Standard Operating
Procedures", has stated that procedures are the cornerstone of a
strong quality system and support meeting the overall goal of
providing the public with safe and effective medical
products.
116. I accept Dr Fordyce's advice that, at the time of the error,
the pharmacy had in place an appropriate Dispensing Prescriptions
SOP. However, I am concerned that more than one staff member failed
to follow the Dispensing Prescriptions SOP, as there are no
initials on the prescription to indicate who dispensed, and who
performed the final check of, the medications dispensed on 8
September 2015, and of the oxybutynin and lignocaine gel dispensed
the next day.
117. Furthermore, I am concerned that the high dose of oxybutynin
was dispensed without the dose first being clarified with the
prescriber, despite the Dispensing Prescriptions SOP stating:
"Check medicine dose, frequency interactions and contraindications,
to ensure the medicine is being given appropriately (eg. correct
dose for age or condition)."
118. Without staff compliance, policies become meaningless.
Ultimately, the pharmacy had a responsibility to ensure that all
staff complied with its SOPs and provided services of an
appropriate standard. I consider that the pharmacy is responsible
for the person who completed the dispensing and final check of the
oxybutynin on 9 September 2015 not being identifiable. In my
opinion, non-compliance with the Dispensing Prescriptions SOP
played a part in Miss A receiving an inappropriate dose of
oxybutynin. Accordingly, I consider that the pharmacy did not
provide services to Miss A with reasonable care and skill and
breached Right 4(1) of the Code.
119. Dr Fordyce advised me that the actions taken by the pharmacy
and its staff following these events were timely and appropriate.
She stated that the changes made to the Dispensing Prescriptions
SOP are very detailed, particularly in regard to dosage
calculations for children, and are appropriate. I accept this
advice.
Opinion: Ms E - Adverse comment
120. Ms E was the pharmacy intern working on 8 September 2015 when
Mr A attended the pharmacy with the prescriptions for Miss A's
medications. Ms E was working with pharmacist Ms B.
121. Ms B said that Ms E took the prescriptions from Mr A and began
processing them through the computer.
122. Ms B stated: "I had to help [Ms E] calculate the volume
required for the doses of Augmentin, Paracetamol, Ibuprofen and
Tramadol, because she was struggling to convert the [milligrams] on
the prescription to [millilitres] required for dosing." Ms B stated
that she reconstituted the antibiotic suspension while Ms E
dispensed the other items on the prescription.
123. Ms E told HDC that she does not recall whether she entered the
prescriptions into the computer, but does recall being involved in
the dispensing of some medications for Miss A that were in
stock.
124. The pharmacy's Dispensing Prescriptions SOP required Ms E to
sign on the date stamp to indicate that she dispensed the
prescription. My expert advisor, pharmacist Sharynne Fordyce,
stated that all persons involved in the dispensing process "were
responsible for initialling or signing for the process they carried
out, so as to identify the processor, dispenser and checker". I am
critical that Ms E did not sign the prescription to indicate her
involvement in the dispensing process.
Recommendations
125. I recommend that Dr C, Ms B, Ms D and the pharmacy each
provide a written apology to Mr and Mrs A, and send this to HDC for
forwarding to Mr and Mrs A within three weeks of the date of this
report.
126. I recommend that the DHB:
a) Give feedback to HDC, within three months of the date of this
report, on the implementation of its new e-prescribing
system.
b) Use this case as an anonymised case study for education for
paediatric medical staff, and report back to HDC on this within
three months of the date of this report.
127. I recommend that the pharmacy :
a) Undertake two audits of compliance with its Dispensing
Prescription SOP by taking two random selections of 30
prescriptions processed during a three-month period, and report
back to HDC on the results of these audits at three and six months
from the date of this report.
b) Use this case as an anonymised case study for education for
future pharmacist or pharmacy intern employees of the
pharmacy.
128. I recommend that the Pharmacy Council of New Zealand consider
whether a review of Ms B's competence is warranted, and report back
to HDC with the results of any review.
129. I recommend that the Ministry of Health actively continue to
support the rollout of ePA across New Zealand's DHBs in both
inpatient and outpatient settings, and work with the sector to
progress an integrated approach to medicines management.
Follow-up actions
130. A copy of this report with details identifying the parties
removed, except the experts who advised on this case, will be sent
to the Medical Council of New Zealand, and it will be advised of Dr
C's name in covering correspondence.
131. A copy of this report with details identifying the parties
removed, except the experts who advised on this case, will be sent
to the Pharmacy Council of New Zealand, and it will be advised of
Ms B's and Ms D's names in covering correspondence.
132. A copy of this report with details identifying the parties
removed, except the experts who advised on this case, will be sent
to the Health Quality Safety Commission, the New Zealand
Pharmacovigilance Centre, the College of Education and Training
branch of the Pharmaceutical Society of New Zealand, and the
Paediatrics and Child Health Division of the Royal Australasian
College of Physicians, and placed on the Health and Disability
Commissioner website, www.hdc.org.nz, for educational
purposes.
Appendix A: Independent paediatric advice to the Commissioner
The following expert advice was obtained from consultant
paediatrician Dr Roger Tuck:
"My name is Roger Tuck and I am a consultant paediatrician
currently employed by the Northland District Health Board. I
obtained my basic medical degree from the University of London in
1972. I obtained Membership of the Royal College of Physicians (UK)
in 1974, Fellowship of the Royal Australasian College of Physicians
in 1981 and Fellowship of the Royal College of Physicians
(Edinburgh) in 1994. I have been a consultant general paediatrician
in New Zealand since 1983.
I have no personal or professional conflict of interest in regard
to this case.
As a general paediatrician, I have considerable experience with
renal and urological conditions of childhood and am familiar with
the surgical procedures described for this young child, and the
drugs used, particularly oxybutynin, the drug in question in this
case.
I have read the material provided by your office including the
guidelines for independent advisors which I will do my best to
follow.
Reasonableness of care provided by [Dr C]:
The information provided would suggest that with the exception of
the prescription error, the care provided both pre and post-event
was of a good standard. The prescription error, as with all
prescription errors, was unacceptable. It would appear that this
was a simple transcription error as there is evidence that [Dr C]
had taken care to calculate an appropriate dose of oxybutynin for
her patient. [Dr C's] subsequent response to this error was prompt
and professional including an approach to the family to apologise.
She has clearly reflected on this error and will undoubtedly take
measures to reduce the risk of further prescribing errors in her
own practice.
Digital prescribing/e prescribing:
As the Commissioner is aware, iatrogenic harm from prescription and
dispensing errors is one of the main causes of avoidable morbidity
and mortality in health systems worldwide. New Zealand is no
exception and as far as I am aware there is no active national
strategy on the implementation of standardised e prescribing in
DHBs throughout NZ, and certainly no significant implementation of
systems nationally. I am aware however that there are piecemeal
efforts in various DHBs. My own view is that a standardised
national system for electronic/digital prescribing throughout New
Zealand's health care settings is well overdue. In the meantime,
patients will continue to be at unnecessary risk of iatrogenic
medication related morbidity and mortality due to inevitable human
error and the risks of manual prescribing and dispensing.
Follow up actions:
This prescribing error was clearly taken seriously and appropriate
internal reviews took place. Basic issues such as legibility, the
use of decimal points and 'trailing zeros' have been re-visited.
Many of the risks of manual prescribing are open to mitigation
using digital systems. Ideally digital/e prescribing should be
available in all health care settings where prescribing takes
place. Algorithms can be embedded in such systems to aid
appropriate medication choices, avoid adverse medication effects
and interactions, and ensure appropriate dosages of
medications.
With particular respect to prescribing for children, a safety and
quality improvement that I am currently pursuing in my own DHB is
the addition of a box on the DHB prescription pad for the patient's
weight. I note that this is also absent from [the DHB's]
prescription pad. Many medications are prescribed on a dose per
weight basis in all age groups, but this is particularly important
in children where doses of medications should be routinely checked
on a dose per weight basis. The addition of a box on the
prescription pad for the patient's weight would provide both a
prompt for careful medication dose calculation and also provide an
important additional check for the dispensing pharmacy to minimise
the risk of inappropriate dosing in the context of manual
prescribing. A digital system could include a mandatory field for
weight.
Community Pharmacy:
I am aware that I have not been asked to comment on this, but I
would like to point out that as prescribing clinicians we rely on
our pharmacy colleagues both within hospital settings and in
community pharmacies to audit our prescriptions. … When [Miss A's]
medication was dispensed there should have been an opportunity to
check the appropriateness of the prescription.
Summary:
Prescribing and dispensing errors are unquestionably serious
departures from acceptable standards of care and can be responsible
for avoidable morbidity and mortality. In [Miss A's] case, had her
parent not been as vigilant and professionally knowledgeable, the
outcome could have been much worse. Technology, in the form of
digital or e prescribing, is available to mitigate the risks of
manual prescribing. Digital systems are in their infancy in NZ. In
the meantime, continuing education of clinical staff on manual
prescribing with continuing innovation to mitigate risks is
essential.
[Dr C's] error would appear to be a simple human error of
transcription. Her response to this was prompt and professional and
elicited the appropriate cascade of enquiry and reflection both
personally, and within the department of paediatric surgery at [the
hospital].
Fortunately in [Miss A's] case, the outcome was largely favourable
and my sympathies and best wishes go to her and to her family for
what must have been a very difficult and upsetting time. My
sympathies also go to [Dr C] as I am aware of the distress that
such an event can cause the involved clinicians.
Dr Roger Tuck. FRACP. FRCP. Consultant Paediatrician."
Appendix B: Independent pharmacy advice to the Commissioner
The following expert advice was obtained from pharmacist Sharynne
Fordyce:
"I, Sharynne Fordyce, have been asked to provide an opinion to the
Commissioner on Case number C15HDC01542. I have read and agreed to
follow the Commissioner's Guidelines for Independent
Advisers.
My qualifications include a Diploma of Pharmacy, and a Masters of
Clinical Pharmacy. I have worked in Retail Pharmacy for over 30
years, both in New Zealand and in England, and also locum for the
Wairarapa DHB. I have also been involved in training and assessing
intern pharmacists.
Expert advice requested
Please review the enclosed documentation and advise whether you
consider the care provided to [Miss A] was reasonable in the
circumstances, and why. In particular, please comment on:
1. The reasonableness of the care provided by each of the
following:
a. [Ms B]
b. [Ms D]
c. [Ms E]
d. [The pharmacy]
2. In this case, who and/or which entity was responsible for
ensuring the correct dose of oxybutynin was dispensed for [Miss
A].
3. Who and/or which entity was responsible for ensuring the
dispensing prescriptions SOP was followed, in particular, that the
prescription was initialled/signed to identify the dispenser and
checker?
4. Was the dispensing prescriptions SOP, in place at the time of
these events, appropriate?
5. Are the changes made to the dispensing prescriptions SOP, in
light of these events, appropriate?
6. Were the other actions taken by the pharmacy and its staff,
following these events, appropriate?
7. Any other matters in this case that you consider warrant
comment.
For each question, it would be helpful if you would advise:
a. What is the standard of care/accepted practice?
b. If there has been a departure from the standard of care or
accepted practice, how significant a departure do you consider this
to be?
c. How would this be viewed by your peers?
d. Recommendations for improvement which may help prevent a similar
occurrence in future.
If you note that there are different versions of events in the
information provided, please provide your advice in the
alternative. For example: whether the care was appropriate based on
scenario (a), and whether it was appropriate based on scenario
(b).
Document copies provided
1. Letter of complaint dated […]
2. Prescription form dated 8 September 2015
3. Incident notification form dated 17 September 2015
4. Apology letter from [Ms B] dated 16 September 2015
5. [The pharmacy's] 'Dispensing Prescriptions' Standard Operating
Procedures (SOPs) (old and new)
6. [The pharmacy's] response and all enclosures dated 17 April
2016
7. [The pharmacy's] further response dated 13 May 2016
8. [Ms B's] response dated 7 April 2016
9. [Ms E] response dated 26 May 2016
Background summary
8 September 2015 a public hospital registrar wrote a prescription
for [Miss A] for, among other things 'Oxybutynin 20mg TDS oral
10/7'.
8 September 2015 [Miss A's] father [Mr A] presented the
prescription to the pharmacy to be filled. [Ms B] was the only
pharmacist on duty at the time, working with [Ms E], intern
pharmacist. Oxybutynin and one other item were not in stock, could
be ordered for next day, father informed by [Ms B]. Rest of
prescription could be dispensed.
[Ms E] started to work on the prescription, generating a label for
oxybutynin. [Ms B] checked the label, which had been put through
for tablets instead of liquid. Noted also 'dose seemed high',
retyped label for liquid and put aside to await stock. Discussed
high dose of oxybutynin with father, who replied [Miss A] had just
come out of surgery. [Ms B] did not check dose further.
9 September 2015, [Ms B] and [Ms D] on duty, [Ms E] on day off.
Oxybutynin liquid arrived, labelled and bagged for delivery. No
initials on prescription form for dispenser or checker. Delivered
that afternoon by [Ms D] to [Miss A's] mother, [Mrs A],
prescription not discussed.
12 September 2015 morning, mother administered 20ml of oxybutynin
liquid to [Miss A]. Concerned about large volume for young child,
internet search revealed overdose, rushed [Miss A] to
hospital.
12 September 2015, later in day [Ms D] received a telephone call
from a surgical registrar at the hospital, explaining what had
happened. [Ms D] sights script, and left a telephone message for
[Mrs A] apologising for error.
14 September 2015 all staff involved told of error.
15 September 2015 Pharmacy Defence Association (PDA) contacted for
advice.
16 September 2015 [the pharmacy] updated its dispensing
prescriptions SOP. [Ms B] wrote letter of apology to [Mr and Mrs
A].
17 September 2015 apology letter delivered to [Mr and Mrs A] and
[Ms B] filled in an incident notification form.
1 .STANDARD OF CARE PROVIDED
a) [Ms B]. Working from [the pharmacy's] training records, it would
appear that in 2015 [Ms B] was in her first year as a registered
pharmacist. On the day of the incident she was in sole charge of an
intern pharmacist, a person a year behind her in training and
experience. [Ms B] followed good prescription and dispensing
practices (in accordance with [the pharmacy's] SOP) by keeping the
customer informed of stock shortages, potential delays and expected
stock arrival time. She allowed [Ms E] to process the prescription,
part of an intern's training, and by [Ms B's] own admission, helped
[Ms E] with calculations she appeared unsure of. When checking the
labels produced by [Ms E] she noticed the mistake with the dosage
form of oxybutynin (tablets not liquid) and noted the high dose,
but did not confirm this dose with the prescriber. The prescription
was written by a registrar from [the hospital], with the associated
implications of specialist knowledge and potentially unusual doses.
Hospital doctors are frequently difficult to locate, to do so can
take hours and many phone calls. However this dose of 20mg three
times daily is three times the maximum dose for an adult, and is
not recommended for use in children under 5 years of age. Therefore
accepted practice would have been to contact the prescriber and not
to dispense the medicine until the dose had been clarified. Not to
have done so would be viewed by myself and my peers as a serious
departure from the accepted standard of care. Receiving assurance
from the father re the 'high' dose is not sufficient. Depending on
which pharmacist checked and labelled the bottle of oxybutynin when
it came in the next day means either [Ms B] or [Ms D] missed
another opportunity to check the unusual dose. This behaviour is
also at odds with the 2014 dispensing prescriptions SOP of [the
pharmacy].
b) [Ms D], although not involved in the actual processing and
dispensing of the script on 8 September, was present in the
dispensary before it was handed out. She had been made aware of [Ms
B's] concern for [Ms E's] inability to independently complete the
calculations involved with the doses on the prescription. As [Ms
E's] preceptor, and the senior pharmacist present, good practice
would have suggested [Ms D] check the prescription, calculations
and labels, as she herself admitted later. It has been noted that
there is no completed training log for [Ms E] as regards knowledge
of SOPs. Not discussing the contents of the bag before handing over
the prescription is also a departure from good practice. As
the child had been in hospital, the parents were likely to be
distressed and may have been confused about drugs and doses. There
are no signatures on the prescription to indicate who processed,
dispensed or checked the prescription. This goes against the 2014
dispensing prescriptions SOP, and lack of identifying signatures
had also been noted on the otherwise excellent audit of [the
pharmacy]. With the volume of prescriptions being dispensed
nationally, accountability for every item dispensed is viewed as
extremely important by the profession.
c) [Ms E] was working as an intern pharmacist at [the pharmacy],
with [Ms D] as her preceptor, when this error occurred … All of
these tasks [entering the prescription into the computer, producing
labels, or completing any dosage calculations] should have been
within the capabilities of an intern. This does not agree with the
description of the incident by either [Ms B] or [Ms D]. Due to the
lack of identifying signatures on the prescription this discrepancy
is hard to solve. However there are annotations (calculations)
visible on the copy of the prescription which may be able to be
linked to either [Ms E] or [Ms B]. … At some stage after this
incident [Ms E] appears to have left the employ of [the pharmacy],
to finish her internship elsewhere. While there is no doubt that
full responsibility must lie with the qualified pharmacists
involved, all interns are trained to dispense each prescription as
if they were solely responsible for the final product, including
attention to dosages.
d) [The pharmacy], at the time of the incident, had in place
appropriate dispensing prescriptions SOPs. It had passed a Ministry
of Health Pharmacy Quality Audit 4 which evaluated procedures,
systems and processes, in September 2014. It employed legally
qualified staff and provided a wide range of services to the local
community. It was able to order in, supply stock and deliver
prescriptions within an appropriate time frame, thus providing an
acceptable standard of care.
2. In this case [Ms B] and [Ms D] were responsible for ensuring the
correct dose of oxybutynin was dispensed for [Miss A]. (Competence
Standards for Pharmacy M1.2, O1.3.3, O1.3.4, O3.1.3 and O3.1.4).
The departure from the accepted standard of care was very
significant.
3. [Ms D], as the owner of [the pharmacy], is the person primarily
responsible for ensuring the dispensing prescriptions SOP is
communicated and followed, or the pharmacist on duty at the time,
being [Ms B]. All three women were responsible for initialling or
signing for the process they carried out, so as to identify the
processor, dispenser and checker. (Competence Standards M1.2,
O1.3.3, O1.3.4, O3.1.3 and O3.1.4). There has been a considerable
departure from acceptable practice in this instance.
4. The dispensing prescriptions SOP, in place at the time of these
events, was entirely appropriate and adequate.
5. The changes made to the dispensing prescriptions SOP, in light
of these events, are very detailed, particularly in regards to
dosage calculations for children, and are appropriate.
6. The actions taken by [the pharmacy] and its staff, following
these events, were timely and appropriate. An earlier involvement
of the Pharmacy Defence Association may have been helpful, and
initiated an earlier filing of the incident notification form. This
may have potentially prevented minor discrepancies in the
pharmacists' reports.
The discrepancies in the recollection of events is disconcerting. …
That neither [Ms B] or [Ms D] could remember whether or not [Ms E]
was present at work on 9 September (her regular day off for which
she was not paid) is surprising. Also unusual is that neither
pharmacist could remember labelling, checking and bagging the
oxybutynin liquid, ready for delivery - a significant departure
from accepted practice. This later omission denied both pharmacists
the chance to investigate a significant and harmful
overdose."
Dr Fordyce provided the following further expert advice on 4 August
2016:
"Having read [Ms D's] reply to my comments I and all my peers would
very much agree with her regarding the need for shared blame for
consequences. As a profession, pharmacists accept that they are the
final barrier between any prescriber errors and the patient,
however both professions have a responsibility to ensure that there
are enough checks and balances in place to limit errors occurring
as much as possible.
In response to [Ms D's] comment regarding the structure of the
intern year and their assignments, I do have a reasonably good idea
of the programme involved. However I was unaware of [Ms E's]
progress through it as it can sometimes differ depending on the
intern and their circumstances. In light of [Ms D's] information I
would like to add the following sentences to my previous comments
on [Ms E].
By September [Ms E] would have been a significant way through her
internship, and only two and a half months away from undergoing her
final assessment for registration in November. Processing a script
such as [Miss A's], with a bit of supervision, should have been
within her capabilities, as should have been the calculations.
…
In summary, throughout the document I have been asked to comment on
how my peers would regard actions that were taken. I think, almost
without exception, my peers would regard this as a tragic incident,
both for [Miss A] and her family, and the pharmacists involved. In
spite of audits, SOPs, checks and balances, human frailties will
always be present."
Appendix C: Prescription form